{ "dataset": "Open Peptide Project Evidence Library", "version": "2026-10-27", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)", "total_pages": 258, "compound_count": 236, "guide_count": 22, "entries": [ { "slug": "bpc-157", "title": "BPC-157", "full_title": "BPC-157: What the evidence says", "kind": "compound", "focus_area": "Muscle, bone & recovery", "focus_area_key": "muscle", "evidence_tier": "Very limited", "card_verdict": "Very limited (3 small uncontrolled clinic reports) · Controlled human trials for tendon, muscle, or gut healing: No human data.", "card_note": "Varies by use, see page", "regulatory_status": "Not FDA-approved · WADA-banned", "pmids": "14554208;16609979;20388964;21030672;27847966;31158953;32334036;34324435;36588717;39325560;40131143;40756949;40789979;42328738;42757290", "nct_ids": "", "search_aliases": "bepecin pl 14736 pl-10 body protection compound pentadecapeptide gut tendon", "last_checked": "2026-10-15", "url": "https://openpeptideproject.org/library/bpc-157/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "5-amino-1mq", "title": "5-Amino-1MQ", "full_title": "5-Amino-1MQ: What the evidence says", "kind": "compound", "focus_area": "Metabolic & weight", "focus_area_key": "metabolic", "evidence_tier": "No human data", "card_verdict": "No human data (fat-loss and muscle claims rest on mouse and cell studies only).", "card_note": "Animal/lab only, see page", "regulatory_status": "Never approved (no openFDA entry) · not on FDA's \"significant safety risks\" page · WADA 2026: not named; may fall under S0 (non-approved substances) ⚠️ [UNVERIFIED] how WADA applies S0 to it", "pmids": "28548833;29155147;30753815;33645410;33707534;34304009;35013352;38969654;39161060;41543936", "nct_ids": "", "search_aliases": "5-amino-1-methylquinolinium nnmt inhibitor", "last_checked": "2026-10-26", "url": "https://openpeptideproject.org/library/5-amino-1mq/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "abaloparatide", "title": "Abaloparatide", "full_title": "Abaloparatide: What the evidence says", "kind": "compound", "focus_area": "Muscle, bone & recovery", "focus_area_key": "muscle", "evidence_tier": "Strong", "card_verdict": "Strong (osteoporosis fractures) · Gray-market: No human data.", "card_note": "Osteosarcoma precautions, see page.", "regulatory_status": "FDA-approved: Tymlos NDA 208743 (Apr 28, 2017) · no boxed warning on current label · WADA: not named on the 2026 List", "pmids": "27533157", "nct_ids": "NCT01343004", "search_aliases": "tymlos pthrp analog osteoporosis bone", "last_checked": "2026-10-25", "url": "https://openpeptideproject.org/library/abaloparatide/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "ace-031", "title": "ACE-031 (ramatercept)", "full_title": "ACE-031 (ramatercept): What the evidence says", "kind": "compound", "focus_area": "Muscle, bone & recovery", "focus_area_key": "muscle", "evidence_tier": "Very limited", "card_verdict": "Very limited · DMD trial stopped for safety.", "card_note": "Development stopped, see page", "regulatory_status": "Never approved, development stopped · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · WADA 2026: prohibited at all times (S4.3)", "pmids": "20466801;23169607;27462804;40312924;41686840", "nct_ids": "NCT00952887;NCT01099761", "search_aliases": "", "last_checked": "2026-10-26", "url": "https://openpeptideproject.org/library/ace-031/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "acetyl-tetrapeptide-3", "title": "Acetyl tetrapeptide-3 (Ac-KGHK-NH2)", "full_title": "Acetyl tetrapeptide-3 (Ac-KGHK-NH2): What the evidence says", "kind": "compound", "focus_area": "Skin, hair & aging", "focus_area_key": "skin", "evidence_tier": "Very limited", "card_verdict": "Very limited (one small trial of a blend).", "card_note": "Cosmetic hair peptide; tested only in a blend", "regulatory_status": "Cosmetic ingredient; not FDA-approved · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · not named by WADA", "pmids": "33584955;40654553;42072405", "nct_ids": "", "search_aliases": "capixyl ac-kgfk acetyl tetrapeptide 3 red clover hair follicle cosmetic peptide", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/acetyl-tetrapeptide-3/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "acetyl-tetrapeptide-5", "title": "Acetyl tetrapeptide-5 (Eyeseryl)", "full_title": "Acetyl tetrapeptide-5 (Eyeseryl): What the evidence says", "kind": "compound", "focus_area": "Skin, hair & aging", "focus_area_key": "skin", "evidence_tier": "No human data", "card_verdict": "No human data (no peer-reviewed human trial found).", "card_note": "Cosmetic peptide marketed for under-eye puffiness", "regulatory_status": "Cosmetic ingredient; not FDA-approved · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · not named by WADA", "pmids": "33849044", "nct_ids": "", "search_aliases": "eyeseryl ac-beta-ala-his-ser-his eye puffiness under-eye bags cosmetic tetrapeptide", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/acetyl-tetrapeptide-5/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "adipotide", "title": "Adipotide (FTPP)", "full_title": "Adipotide (FTPP): What the evidence says", "kind": "compound", "focus_area": "Metabolic & weight", "focus_area_key": "metabolic", "evidence_tier": "No human data", "card_verdict": "No human data (weight-loss claims rest on animal studies; 4-person cancer trial terminated with no results posted).", "card_note": "Kidney toxicity in animals, see page", "regulatory_status": "Never approved · Not on FDA 503A or 503B bulk lists · WADA 2026: not named; likely S0 ⚠️", "pmids": "15133506;22072637;22539771;23871959", "nct_ids": "NCT01262664", "search_aliases": "", "last_checked": "2026-10-26", "url": "https://openpeptideproject.org/library/adipotide/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "adropin", "title": "Adropin", "full_title": "Adropin: What the evidence says", "kind": "compound", "focus_area": "Metabolic & weight", "focus_area_key": "metabolic", "evidence_tier": "No human data", "card_verdict": "No human data (blood-level studies only; never tested as a treatment in people).", "card_note": "Natural metabolic peptide; never given to people as a treatment", "regulatory_status": "Not approved anywhere · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · not named on WADA's 2026 list; as a drug not approved anywhere for human use it falls under S0 (non-approved substances)", "pmids": "19041763;20837912;34897581;35955453;37029398", "nct_ids": "", "search_aliases": "enho energy homeostasis-associated protein endothelial metabolic hormone", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/adropin/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "ahk-cu", "title": "AHK-Cu", "full_title": "AHK-Cu: What the evidence says", "kind": "compound", "focus_area": "Skin, hair & aging", "focus_area_key": "skin", "evidence_tier": "No human data", "card_verdict": "No human data (hair-growth claims rest on one human hair-follicle lab study; skin claims untested in people).", "card_note": "One lab study only, see page", "regulatory_status": "Not approved as a drug · Not on FDA 503A or 503B bulk lists · No FDA safety-risk entry", "pmids": "17703734", "nct_ids": "", "search_aliases": "copper tripeptide-3 alanine histidine lysine hair growth", "last_checked": "2026-10-26", "url": "https://openpeptideproject.org/library/ahk-cu/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "aicar", "title": "AICAR (acadesine)", "full_title": "AICAR (acadesine): What the evidence says", "kind": "compound", "focus_area": "Metabolic & weight", "focus_area_key": "metabolic", "evidence_tier": "No human data", "card_verdict": "Tested, not shown (coronary bypass RCT) · Endurance: mouse data only.", "card_note": "Varies by use, see page", "regulatory_status": "Never approved · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · WADA 2026: prohibited at all times (S4.4.1, AMPK activators)", "pmids": "18674809;20225061;22782417;23228986;34064363", "nct_ids": "NCT00872001", "search_aliases": "acadesine zmp ampk activator", "last_checked": "2026-10-26", "url": "https://openpeptideproject.org/library/aicar/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "albiglutide", "title": "Albiglutide (Tanzeum)", "full_title": "Albiglutide (Tanzeum): What the evidence says", "kind": "compound", "focus_area": "Metabolic & weight", "focus_area_key": "metabolic", "evidence_tier": "Strong", "card_verdict": "Strong (FDA-approved diabetes & CV outcomes; commercially discontinued).", "card_note": "Discontinued prescription drug", "regulatory_status": "FDA-licensed (BLA 125431), discontinued · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · not named by WADA", "pmids": "27904741;30291013", "nct_ids": "", "search_aliases": "tanzeum eperzan glp-1 diabetes", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/albiglutide/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "amycretin", "title": "Amycretin (Zenagamtide)", "full_title": "Amycretin (Zenagamtide): What the evidence says", "kind": "compound", "focus_area": "Metabolic & weight", "focus_area_key": "metabolic", "evidence_tier": "Limited", "card_verdict": "Limited (weight loss & type 2 diabetes in early phase 1b/2 trials; phase 3 starting).", "card_note": "", "regulatory_status": "Not FDA-approved (no Drugs@FDA record) · EU, Japan, China: [UNVERIFIED] not checked against EMA, PMDA or NMPA · WADA: not named; S0 (unapproved substances) likely applies", "pmids": "40550229;40550231;42443140;42532079;42532080;42853576", "nct_ids": "NCT06064006;NCT06542874;NCT07339423;NCT07533175;NCT07567001", "search_aliases": "zenagamtide nnc0487-0111 glp-1 amylin dual agonist", "last_checked": "2026-10-25", "url": "https://openpeptideproject.org/library/amycretin/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "anamorelin", "title": "Anamorelin (ONO-7643)", "full_title": "Anamorelin (ONO-7643): What the evidence says", "kind": "compound", "focus_area": "Muscle, bone & recovery", "focus_area_key": "muscle", "evidence_tier": "Moderate", "card_verdict": "Moderate (cancer cachexia weight; no strength gain) · Not FDA-approved.", "card_note": "Varies by use, see page", "regulatory_status": "Not FDA-approved · approved in Japan · EU refusal 2017 · not on the 503A/503B lists or FDA's safety-risk page · WADA 2026: named under S2.2.4, prohibited at all times", "pmids": "26906526;28472437;33382205;37709824;38693813", "nct_ids": "NCT01387269;NCT01387282;NCT03637816;NCT03743051;NCT03743064", "search_aliases": "", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/anamorelin/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "andarine-s4", "title": "Andarine (S-4, GTx-007)", "full_title": "Andarine (S-4, GTx-007): What the evidence says", "kind": "compound", "focus_area": "Muscle, bone & recovery", "focus_area_key": "muscle", "evidence_tier": "No human data", "card_verdict": "No human data (rat studies only; not a peptide).", "card_note": "Unapproved SARM; never shown to work in people; small molecule", "regulatory_status": "Not FDA-approved · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · named on WADA S1.2", "pmids": "15204699;16099859;21816554;23427117;29183075;36479151;39755947", "nct_ids": "", "search_aliases": "andarine s-4 s4 gtx-007 gtx007 non-steroidal sarm selective androgen receptor modulator", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/andarine-s4/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "aod-9604", "title": "AOD-9604 / HGH Fragment 176-191", "full_title": "AOD-9604 / HGH Fragment 176-191: What the evidence says", "kind": "compound", "focus_area": "Metabolic & weight", "focus_area_key": "metabolic", "evidence_tier": "No human data", "card_verdict": "Tested, not shown (oral weight loss) · Injected weight loss, joints, muscle: No human data.", "card_note": "Varies by use, see page", "regulatory_status": "Not FDA-approved · FDA advisers voted 12–0 against adding it to the 503A list (Dec 2024); no final FDA decision found · not on the 503A or 503B category lists · on FDA's significant-safety-risks page (nominations withdrawn) · WADA 2026: banned at all times (S2.2.3, both names listed)", "pmids": "7987248;8358331;11146367;11673763;11713213;15134286;24124033;24976118;25208511;26275694;41966639;42395176", "nct_ids": "", "search_aliases": "", "last_checked": "2026-10-26", "url": "https://openpeptideproject.org/library/aod-9604/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "apitegromab", "title": "Apitegromab (Isembyld, SRK-015)", "full_title": "Apitegromab (Isembyld, SRK-015): What the evidence says", "kind": "compound", "focus_area": "Muscle, bone & recovery", "focus_area_key": "muscle", "evidence_tier": "Strong", "card_verdict": "Strong (FDA-approved for SMA; no evidence for healthy muscle gain).", "card_note": "FDA-approved SMA antibody; myostatin blocker", "regulatory_status": "FDA-approved · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · named on WADA S4.3", "pmids": "40818473", "nct_ids": "NCT03921528;NCT05156320", "search_aliases": "isembyld srk-015 promyostatin spinal muscular atrophy sma", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/apitegromab/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "apraglutide", "title": "Apraglutide", "full_title": "Apraglutide: What the evidence says", "kind": "compound", "focus_area": "Heart, blood & gut", "focus_area_key": "cardio", "evidence_tier": "Moderate", "card_verdict": "Moderate (phase 3 short bowel syndrome RCT; investigational).", "card_note": "Investigational; second phase 3 under way", "regulatory_status": "Investigational, not FDA-approved · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · not named on WADA's 2026 list", "pmids": "32075870;34287970;35233802;37316329;42692160", "nct_ids": "NCT04627025;NCT05018286;NCT07742735", "search_aliases": "fe 203799 glp-2 short bowel syndrome", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/apraglutide/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "ara-290", "title": "ARA-290 (cibinetide)", "full_title": "ARA-290 (cibinetide): What the evidence says", "kind": "compound", "focus_area": "Brain, mood & sleep", "focus_area_key": "neuro", "evidence_tier": "Very limited", "card_verdict": "Very limited (sarcoidosis nerve symptoms, type 2 diabetes, macular edema) · Healing & recovery in healthy people: No human data.", "card_note": "Mixed use: small company-run disease trials only; the healing and recovery uses it is sold for are animal data. See page.", "regulatory_status": "Not approved anywhere · FDA orphan designation (2011) · EU orphan designations (2013, 2016) · 503A: Category 3 · WADA 2026: not named; our reading is that S2.1.5 \"innate repair receptor agonists\" covers it (prohibited at all times), not a WADA ruling", "pmids": "23168581;24136731;24529189;24555851;25387363;26431906;28475703;29392190;32674280;38488446", "nct_ids": "NCT02039687;NCT06626971", "search_aliases": "cibinetide phbsp erythropoietin innate repair receptor neuropathy sarcoidosis", "last_checked": "2026-10-26", "url": "https://openpeptideproject.org/library/ara-290/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "argireline", "title": "Argireline (acetyl hexapeptide-3/-8)", "full_title": "Argireline (acetyl hexapeptide-3/-8): What the evidence says", "kind": "compound", "focus_area": "Skin, hair & aging", "focus_area_key": "skin", "evidence_tier": "Limited", "card_verdict": "Limited (topical wrinkles) · Injection: No data.", "card_note": "Topical only, see page", "regulatory_status": "Cosmetic ingredient, not an approved drug · 503B Category 3 (acetyl hexapeptide-3); not on the 503A list · WADA: not named", "pmids": "18498523;23146065;23417317;24754410;33748252;40673537", "nct_ids": "", "search_aliases": "acetyl hexapeptide-8 acetyl hexapeptide-3 botox-like wrinkle peptide", "last_checked": "2026-10-26", "url": "https://openpeptideproject.org/library/argireline/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "avexitide", "title": "Avexitide (exendin 9-39)", "full_title": "Avexitide (exendin 9-39): What the evidence says", "kind": "compound", "focus_area": "Metabolic & weight", "focus_area_key": "metabolic", "evidence_tier": "Limited", "card_verdict": "Limited (small RCTs published; positive phase 3 reported only by the company so far).", "card_note": "Investigational GLP-1 blocker for low blood sugar after gastric bypass", "regulatory_status": "Investigational · not FDA-approved · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · not named on WADA's 2026 list; as a drug not approved anywhere for human use it falls under S0 (non-approved substances)", "pmids": "22855730;27975209;28776922;29077992;32250530;33616643;35416981;42744082", "nct_ids": "NCT00571324;NCT03373435;NCT04652479;NCT06747468;NCT07582874", "search_aliases": "exendin 9-39 exendin(9-39) ex-9-39 glp-1 receptor antagonist post-bariatric hypoglycemia pbh congenital hyperinsulinism prevent", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/avexitide/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "azd5004", "title": "AZD5004 (elecoglipron, ECC5004)", "full_title": "AZD5004 (elecoglipron, ECC5004): What the evidence says", "kind": "compound", "focus_area": "Metabolic & weight", "focus_area_key": "metabolic", "evidence_tier": "Moderate", "card_verdict": "Moderate (one phase 2 RCT; not a peptide).", "card_note": "Investigational daily GLP-1 pill; small molecule", "regulatory_status": "Investigational · not FDA-approved · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · not named on WADA's 2026 list; as a drug not approved anywhere for human use it falls under S0 (non-approved substances)", "pmids": "42259337;42896872", "nct_ids": "NCT06579092;NCT06988553", "search_aliases": "elecoglipron ecc5004 oral small-molecule glp-1 agonist", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/azd5004/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "b7-33", "title": "B7-33", "full_title": "B7-33: What the evidence says", "kind": "compound", "focus_area": "Heart, blood & gut", "focus_area_key": "cardio", "evidence_tier": "No human data", "card_verdict": "No human data (heart, kidney & lung anti-fibrosis claims rest on rodent and cell studies only).", "card_note": "Animal/lab only, see page", "regulatory_status": "Never approved · Not on FDA 503A or 503B bulk lists · WADA 2026: not named; likely S0 ⚠️", "pmids": "28478069;30155023;30641102;31713411;32295457;36753958;37047588;37628851", "nct_ids": "", "search_aliases": "", "last_checked": "2026-10-26", "url": "https://openpeptideproject.org/library/b7-33/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "bam15", "title": "BAM15", "full_title": "BAM15: What the evidence says", "kind": "compound", "focus_area": "Metabolic & weight", "focus_area_key": "metabolic", "evidence_tier": "No human data", "card_verdict": "No human data (mouse studies only; not a peptide).", "card_note": "Preclinical mitochondrial uncoupler; small molecule", "regulatory_status": "Not approved anywhere · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · named on WADA S4.4.1", "pmids": "21739343;24634817;32078021;32409697;32519812;35304976;40639664", "nct_ids": "", "search_aliases": "bam-15 mitochondrial protonophore uncoupler furazanopyrazine", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/bam15/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "bimagrumab", "title": "Bimagrumab (BYM338, LY3985863)", "full_title": "Bimagrumab (BYM338, LY3985863): What the evidence says", "kind": "compound", "focus_area": "Muscle, bone & recovery", "focus_area_key": "muscle", "evidence_tier": "Moderate", "card_verdict": "Moderate (phase 2, investigational, body composition) · No proven gain in strength or function.", "card_note": "Varies by use, see page", "regulatory_status": "Investigational, not approved anywhere · antibody, so not a 503A/503B bulk substance; not on FDA's safety-risk page · WADA 2026: named under S4.3, prohibited at all times", "pmids": "31397289;33074327;33439265;38218536;39251484;41772149", "nct_ids": "NCT03005288;NCT05616013;NCT05933499;NCT06643728", "search_aliases": "bym338 ly3985863 activin receptor type ii myostatin lean mass", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/bimagrumab/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "biotinoyl-tripeptide-1", "title": "Biotinoyl tripeptide-1 (biotinyl-GHK)", "full_title": "Biotinoyl tripeptide-1 (biotinyl-GHK): What the evidence says", "kind": "compound", "focus_area": "Skin, hair & aging", "focus_area_key": "skin", "evidence_tier": "Very limited", "card_verdict": "Very limited (only tested in multi-ingredient blends).", "card_note": "Cosmetic hair peptide; tested only in blends", "regulatory_status": "Cosmetic ingredient; not FDA-approved · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · not named by WADA", "pmids": "37292551;37990760;39609969;40654553", "nct_ids": "", "search_aliases": "biotin-ghk procapil widelash biotinoyl tripeptide 1 hair growth eyelash cosmetic peptide", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/biotinoyl-tripeptide-1/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "bivalirudin", "title": "Bivalirudin (Angiomax)", "full_title": "Bivalirudin (Angiomax): What the evidence says", "kind": "compound", "focus_area": "Heart, blood & gut", "focus_area_key": "cardio", "evidence_tier": "Strong", "card_verdict": "Strong (FDA-approved hospital direct thrombin inhibitor for PCI).", "card_note": "FDA-approved anticoagulant used during angioplasty", "regulatory_status": "FDA-approved · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · not named by WADA", "pmids": "12588269;18499566", "nct_ids": "NCT00433966", "search_aliases": "angiomax angiomax rtu hirulog direct thrombin inhibitor pci", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/bivalirudin/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "bonomarlot", "title": "Bonomarlot (bone marrow peptide complex)", "full_title": "Bonomarlot (bone marrow peptide complex): What the evidence says", "kind": "compound", "focus_area": "Longevity & bioregulators", "focus_area_key": "longevity", "evidence_tier": "No human data", "card_verdict": "No human data (no indexed peer-reviewed clinical trial found).", "card_note": "Russian oral tissue-extract supplement; no indexed trials", "regulatory_status": "Not FDA-approved · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · not named by WADA", "pmids": "32399807", "nct_ids": "", "search_aliases": "a-20 bone marrow cytomax khavinson", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/bonomarlot/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "bortezomib", "title": "Bortezomib (Velcade, PS-341)", "full_title": "Bortezomib (Velcade, PS-341): What the evidence says", "kind": "compound", "focus_area": "Immune & antimicrobial", "focus_area_key": "immune", "evidence_tier": "Strong", "card_verdict": "Strong (FDA-approved for multiple myeloma and mantle cell lymphoma).", "card_note": "FDA-approved dipeptide boronic-acid proteasome inhibitor", "regulatory_status": "FDA-approved · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · not named by WADA", "pmids": "15958804", "nct_ids": "", "search_aliases": "velcade ps-341 boronic acid proteasome inhibitor multiple myeloma", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/bortezomib/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "bronchogen", "title": "Bronchogen", "full_title": "Bronchogen: What the evidence says", "kind": "compound", "focus_area": "Longevity & bioregulators", "focus_area_key": "longevity", "evidence_tier": "No human data", "card_verdict": "No human data · No published human studies of the marketed use (bronchitis/COPD).", "card_note": "No published human study tests the bronchitis/COPD use it is sold for; rat-model work only.", "regulatory_status": "Not FDA-approved (no Drugs@FDA entry found) · Russia: registration status [UNVERIFIED] · WADA: not named on the 2026 List ; S0 status [UNVERIFIED]", "pmids": "21240358;26468022;27909961;30199201", "nct_ids": "", "search_aliases": "aedl ala-glu-asp-leu bronchial bioregulator khavinson", "last_checked": "2026-10-25", "url": "https://openpeptideproject.org/library/bronchogen/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "cagrilintide", "title": "Cagrilintide", "full_title": "Cagrilintide: What the evidence says", "kind": "compound", "focus_area": "Metabolic & weight", "focus_area_key": "metabolic", "evidence_tier": "Limited", "card_verdict": "Limited (weight, alone) · Type 2 diabetes (alone): Very limited.", "card_note": "Varies by use, see page", "regulatory_status": "Not FDA-approved · cannot be used in compounding (FDA) · FDA has warned online sellers of \"research\" cagrilintide · EU, UK, Japan, China: [UNVERIFIED] no approval found, not checked against EMA/PMDA/NMPA · WADA: not named; S0 (unapproved substances) likely applies", "pmids": "33894838;34798060;37364590;39279639;40544433;42251859", "nct_ids": "NCT03600480;NCT03856047;NCT04982575;NCT05804162", "search_aliases": "am833 nnc0174-0833 long-acting amylin analog", "last_checked": "2026-10-25", "url": "https://openpeptideproject.org/library/cagrilintide/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "cagrisema", "title": "CagriSema", "full_title": "CagriSema: What the evidence says", "kind": "compound", "focus_area": "Metabolic & weight", "focus_area_key": "metabolic", "evidence_tier": "Moderate", "card_verdict": "Moderate (weight loss & type 2 diabetes in phase 3 trials; not yet FDA-approved).", "card_note": "", "regulatory_status": "Not FDA-approved · US application submitted per Novo Nordisk [UNVERIFIED] · cagrilintide cannot be used in compounding (FDA) · FDA has warned sellers of a \"cagrilintide and semaglutide\" research product · EU and other countries: [UNVERIFIED] not checked against EMA/PMDA/NMPA · WADA: not named; cagrilintide component unapproved, so S0 may apply", "pmids": "33894838;37364590;40544432;40544433;41328546;42009015;42251856;42251859;42251860;42838477", "nct_ids": "NCT03600480;NCT04982575;NCT05394519;NCT05567796;NCT05669755;NCT05813925;NCT06065540;NCT06131437;NCT06323161;NCT06323174", "search_aliases": "cagrilintide semaglutide combo", "last_checked": "2026-10-25", "url": "https://openpeptideproject.org/library/cagrisema/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "calcitonin", "title": "Calcitonin-Salmon (Miacalcin / Fortical)", "full_title": "Calcitonin-Salmon (Miacalcin / Fortical): What the evidence says", "kind": "compound", "focus_area": "Muscle, bone & recovery", "focus_area_key": "muscle", "evidence_tier": "Moderate", "card_verdict": "Moderate (FDA-approved; weak fracture RCT data and pooled cancer signal).", "card_note": "Prescription drug", "regulatory_status": "FDA-approved; nasal sprays discontinued · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · not named by WADA", "pmids": "3365896;10996576;25516047", "nct_ids": "", "search_aliases": "miacalcin fortical calcimar salmon calcitonin hypercalcemia paget", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/calcitonin/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "cardiogen", "title": "Cardiogen", "full_title": "Cardiogen: What the evidence says", "kind": "compound", "focus_area": "Longevity & bioregulators", "focus_area_key": "longevity", "evidence_tier": "No human data", "card_verdict": "No human data (heart-repair claims rest on developer-led rat tissue and cell studies only).", "card_note": "Animal/lab data only (developer-led), see page", "regulatory_status": "Not FDA-approved (no Drugs@FDA record) · Russia: registration status [UNVERIFIED] · WADA 2026: not named; S0 (unapproved substances) likely applies", "pmids": "17152728;20210190;36611900", "nct_ids": "", "search_aliases": "aedr ala-glu-asp-arg heart bioregulator khavinson", "last_checked": "2026-10-25", "url": "https://openpeptideproject.org/library/cardiogen/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "carfilzomib", "title": "Carfilzomib (Kyprolis, PR-171)", "full_title": "Carfilzomib (Kyprolis, PR-171): What the evidence says", "kind": "compound", "focus_area": "Immune & antimicrobial", "focus_area_key": "immune", "evidence_tier": "Strong", "card_verdict": "Strong (FDA-approved for multiple myeloma; serious cardiac risks).", "card_note": "FDA-approved peptide proteasome inhibitor", "regulatory_status": "FDA-approved · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · not named by WADA", "pmids": "25482145", "nct_ids": "", "search_aliases": "kyprolis pr-171 proteasome inhibitor multiple myeloma", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/carfilzomib/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "carnosine", "title": "Carnosine (L-carnosine, β-alanyl-L-histidine)", "full_title": "Carnosine (L-carnosine, β-alanyl-L-histidine): What the evidence says", "kind": "compound", "focus_area": "Longevity & bioregulators", "focus_area_key": "longevity", "evidence_tier": "Limited", "card_verdict": "Limited (small, mixed supplement trials; not an FDA-approved drug).", "card_note": "Dietary-supplement dipeptide found in muscle", "regulatory_status": "Not FDA-approved as a drug · L-carnosine in Category 3 on FDA's 503A and 503B bulk lists · not on FDA's safety-risk page · not named by WADA", "pmids": "26682691;28245346;31828942;34884603;37049610;38004228;40999397;42123986", "nct_ids": "", "search_aliases": "l-carnosine beta-alanyl-l-histidine n-acetylcarnosine nac eye drops beta-alanine dipeptide glycation", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/carnosine/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "cartalax", "title": "Cartalax", "full_title": "Cartalax: What the evidence says", "kind": "compound", "focus_area": "Longevity & bioregulators", "focus_area_key": "longevity", "evidence_tier": "No human data", "card_verdict": "No human data · No published studies of the marketed use (cartilage).", "card_note": "No published study tests the cartilage or joint use it is sold for.", "regulatory_status": "Not FDA-approved (no Drugs@FDA entry found) · Russia: registration status [UNVERIFIED] · WADA: not named on the 2026 List ; S0 status [UNVERIFIED]", "pmids": "26515176;27259496;33231794", "nct_ids": "", "search_aliases": "aed ala-glu-asp cartilage bioregulator khavinson", "last_checked": "2026-10-25", "url": "https://openpeptideproject.org/library/cartalax/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "cerebrolysin", "title": "Cerebrolysin", "full_title": "Cerebrolysin: What the evidence says", "kind": "compound", "focus_area": "Brain, mood & sleep", "focus_area_key": "neuro", "evidence_tier": "Limited", "card_verdict": "Limited (stroke recovery, mixed results) · Nootropic use: No human data.", "card_note": "Varies by use, see page.", "regulatory_status": "Not FDA-approved (no Drugs@FDA entry found) · Austria: authorized, prescription-only (BASG label) · Russia, Asia: [UNVERIFIED] · WADA: not named on the 2026 List", "pmids": "22282884;26564102;31710397;33620612;37818733", "nct_ids": "", "search_aliases": "", "last_checked": "2026-10-25", "url": "https://openpeptideproject.org/library/cerebrolysin/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "cerluten", "title": "Cerluten (brain peptide complex)", "full_title": "Cerluten (brain peptide complex): What the evidence says", "kind": "compound", "focus_area": "Longevity & bioregulators", "focus_area_key": "longevity", "evidence_tier": "No human data", "card_verdict": "No human data (no indexed peer-reviewed clinical trial found).", "card_note": "Russian oral tissue-extract supplement; no indexed trials", "regulatory_status": "Not FDA-approved · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · not named by WADA", "pmids": "32593244", "nct_ids": "", "search_aliases": "a-5 brain cytomax khavinson", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/cerluten/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "cetrorelix", "title": "Cetrorelix (Cetrotide)", "full_title": "Cetrorelix (Cetrotide): What the evidence says", "kind": "compound", "focus_area": "Hormones & fertility", "focus_area_key": "endocrine", "evidence_tier": "Strong", "card_verdict": "Strong (FDA-approved for IVF ovulation prevention) · Off-label uses: No human data.", "card_note": "Prescription fertility drug; no evidence for other uses", "regulatory_status": "FDA-approved, NDA 021197; generics approved · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · not named on WADA's 2026 list", "pmids": "10686191;36594696", "nct_ids": "", "search_aliases": "cetrotide gnrh antagonist ivf fertility", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/cetrorelix/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "chitomur", "title": "Chitomur (bladder peptide complex)", "full_title": "Chitomur (bladder peptide complex): What the evidence says", "kind": "compound", "focus_area": "Longevity & bioregulators", "focus_area_key": "longevity", "evidence_tier": "Very limited", "card_verdict": "Very limited (two small Russian blind trials; no independent replication).", "card_note": "Russian oral bladder-extract supplement", "regulatory_status": "Not FDA-approved · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · not named by WADA", "pmids": "24640697;28976156", "nct_ids": "", "search_aliases": "a-12 bladder cytomax khavinson", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/chitomur/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "chonluten", "title": "Chonluten", "full_title": "Chonluten: What the evidence says", "kind": "compound", "focus_area": "Longevity & bioregulators", "focus_area_key": "longevity", "evidence_tier": "No human data", "card_verdict": "No human data · No published studies of the marketed use (lungs/bronchi).", "card_note": "No published study tests the lung or bronchial use it is sold for.", "regulatory_status": "Not FDA-approved (no Drugs@FDA entry found) · Russia: registration status [UNVERIFIED] · WADA: not named on the 2026 List ; S0 status [UNVERIFIED]", "pmids": "35408963;36979488", "nct_ids": "", "search_aliases": "edg glu-asp-gly bronchial bioregulator khavinson", "last_checked": "2026-10-25", "url": "https://openpeptideproject.org/library/chonluten/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "cjc-1295", "title": "CJC-1295", "full_title": "CJC-1295: What the evidence says", "kind": "compound", "focus_area": "Hormones & fertility", "focus_area_key": "endocrine", "evidence_tier": "Limited", "card_verdict": "Limited (raises growth hormone & IGF-1, DAC version) · Muscle, fat loss, recovery, anti-aging, or no-DAC version: No human data.", "card_note": "Varies by use, see page", "regulatory_status": "Not FDA-approved · FDA lists it as formerly Category 2, nomination withdrawn; FDA advisers voted against compounding it (Dec 2024) · WADA 2026: banned at all times (S2.2.4)", "pmids": "15817669;16352683;16822960;17018654;30136411", "nct_ids": "NCT00267527", "search_aliases": "", "last_checked": "2026-10-15", "url": "https://openpeptideproject.org/library/cjc-1295/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "colistin", "title": "Colistin (colistimethate sodium, polymyxin E)", "full_title": "Colistin (colistimethate sodium, polymyxin E): What the evidence says", "kind": "compound", "focus_area": "Immune & antimicrobial", "focus_area_key": "immune", "evidence_tier": "Moderate", "card_verdict": "Moderate (FDA-approved last-resort antibiotic; high kidney and nerve toxicity).", "card_note": "FDA-approved last-resort polymyxin antibiotic", "regulatory_status": "FDA-approved · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · not named by WADA", "pmids": "30557685;40682801", "nct_ids": "", "search_aliases": "coly-mycin m colistimethate sodium polymyxin e antibiotic", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/colistin/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "cortagen", "title": "Cortagen", "full_title": "Cortagen: What the evidence says", "kind": "compound", "focus_area": "Longevity & bioregulators", "focus_area_key": "longevity", "evidence_tier": "No human data", "card_verdict": "No human data (animal and lab data only).", "card_note": "Russian lab studies only, see page", "regulatory_status": "Not approved · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · WADA: not named", "pmids": "11276314;12134478;15085253;15159690;21476278", "nct_ids": "", "search_aliases": "aedp ala-glu-asp-pro brain bioregulator khavinson", "last_checked": "2026-10-26", "url": "https://openpeptideproject.org/library/cortagen/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "cortexin", "title": "Cortexin", "full_title": "Cortexin: What the evidence says", "kind": "compound", "focus_area": "Brain, mood & sleep", "focus_area_key": "neuro", "evidence_tier": "Limited", "card_verdict": "Limited (ischemic stroke) · Nootropic use: No human data.", "card_note": "Varies by use, see page", "regulatory_status": "Not FDA-approved (no Drugs@FDA record) · Russia: reported as registered in GRLS [UNVERIFIED] · WADA 2026: not named; S0 depends on Russian registration status [UNVERIFIED]", "pmids": "19431244;24874316;26356623;30335070;33449527;37818733;41524350;42133422", "nct_ids": "", "search_aliases": "", "last_checked": "2026-10-25", "url": "https://openpeptideproject.org/library/cortexin/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "corticotropin-acth", "title": "Repository corticotropin injection (Acthar Gel, Purified Cortrophin Gel)", "full_title": "Repository corticotropin injection (Acthar Gel, Purified Cortrophin Gel): What the evidence says", "kind": "compound", "focus_area": "Hormones & fertility", "focus_area_key": "endocrine", "evidence_tier": "Moderate", "card_verdict": "Moderate (FDA-approved; few modern RCTs and not shown better than steroids for most uses).", "card_note": "FDA-approved porcine ACTH gel", "regulatory_status": "FDA-approved · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · prohibited at all times (WADA S2.2.2)", "pmids": "8604274;34902005;34984839", "nct_ids": "", "search_aliases": "acthar gel purified cortrophin gel acth adrenocorticotropic hormone repository corticotropin injection infantile spasms", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/corticotropin-acth/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "cosyntropin", "title": "Cosyntropin (Cortrosyn, tetracosactide, ACTH 1-24)", "full_title": "Cosyntropin (Cortrosyn, tetracosactide, ACTH 1-24): What the evidence says", "kind": "compound", "focus_area": "Hormones & fertility", "focus_area_key": "endocrine", "evidence_tier": "Moderate", "card_verdict": "Moderate (FDA-approved standard diagnostic for adrenal insufficiency; better at ruling in than ruling out).", "card_note": "FDA-approved diagnostic ACTH fragment", "regulatory_status": "FDA-approved · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · prohibited at all times (WADA S2.2.2)", "pmids": "26649617", "nct_ids": "", "search_aliases": "cortrosyn synacthen tetracosactide acth 1-24 acth(1-24) cosyntropin stimulation test adrenal insufficiency", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/cosyntropin/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "cotadutide", "title": "Cotadutide (MEDI0382)", "full_title": "Cotadutide (MEDI0382): What the evidence says", "kind": "compound", "focus_area": "Metabolic & weight", "focus_area_key": "metabolic", "evidence_tier": "Moderate", "card_verdict": "Moderate (phase 2b T2D/MASH/CKD RCTs; development discontinued).", "card_note": "Investigational; discontinued", "regulatory_status": "Never approved; discontinued · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · not named by WADA", "pmids": "29945727;34016612;35403793;38729399;39218393", "nct_ids": "NCT05364931;NCT05668936", "search_aliases": "medi0382 glp-1 glucagon dual agonist", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/cotadutide/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "crystagen", "title": "Crystagen", "full_title": "Crystagen: What the evidence says", "kind": "compound", "focus_area": "Longevity & bioregulators", "focus_area_key": "longevity", "evidence_tier": "No human data", "card_verdict": "No human data (immune claims rest on rodent and lab cell studies only).", "card_note": "Rodent and lab studies only; no human trials found.", "regulatory_status": "Not FDA-approved (no Drugs@FDA entry found) · Russia: registration status [UNVERIFIED] · WADA: not named on the 2026 List ; S0 status [UNVERIFIED]", "pmids": "27909961;28976144", "nct_ids": "", "search_aliases": "edp glu-asp-pro immune bioregulator khavinson", "last_checked": "2026-10-25", "url": "https://openpeptideproject.org/library/crystagen/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "ct-388", "title": "CT-388 (enicepatide, RO7795068)", "full_title": "CT-388 (enicepatide, RO7795068): What the evidence says", "kind": "compound", "focus_area": "Metabolic & weight", "focus_area_key": "metabolic", "evidence_tier": "Limited", "card_verdict": "Limited (phase 1 published; phase 2 done but unpublished; phase 3 under way).", "card_note": "Investigational weekly GLP-1/GIP injection", "regulatory_status": "Investigational · not FDA-approved · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · not named on WADA's 2026 list; as a drug not approved anywhere for human use it falls under S0 (non-approved substances)", "pmids": "41319798;42768195", "nct_ids": "NCT06525935;NCT07351045;NCT07889648", "search_aliases": "enicepatide ro7795068 dual glp-1 gip modulator", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/ct-388/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "ct-996", "title": "CT-996 (RO7795081)", "full_title": "CT-996 (RO7795081): What the evidence says", "kind": "compound", "focus_area": "Metabolic & weight", "focus_area_key": "metabolic", "evidence_tier": "Very limited", "card_verdict": "Very limited (phase 1 only, no published results; not a peptide).", "card_note": "Investigational daily GLP-1 pill; small molecule", "regulatory_status": "Investigational · not FDA-approved · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · not named on WADA's 2026 list; as a drug not approved anywhere for human use it falls under S0 (non-approved substances)", "pmids": "", "nct_ids": "NCT05814107;NCT06809608;NCT07499050", "search_aliases": "ro7795081 oral small-molecule glp-1 agonist", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/ct-996/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "dalargin", "title": "Dalargin", "full_title": "Dalargin: What the evidence says", "kind": "compound", "focus_area": "Heart, blood & gut", "focus_area_key": "cardio", "evidence_tier": "Limited", "card_verdict": "Limited (Soviet ulcer trials; lost to misoprostol in RCT; Russian phase 3 results unposted).", "card_note": "Russian enkephalin-analog ulcer drug; not approved in US", "regulatory_status": "Not FDA-approved · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · not named by WADA", "pmids": "1279830;1811815;2193190;2416590;2640568;3067406;3554590", "nct_ids": "NCT04346693;NCT07404358", "search_aliases": "leu-enkephalin analog d-ala2 hexapeptide", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/dalargin/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "danuglipron", "title": "Danuglipron (PF-06882961)", "full_title": "Danuglipron (PF-06882961): What the evidence says", "kind": "compound", "focus_area": "Metabolic & weight", "focus_area_key": "metabolic", "evidence_tier": "Moderate", "card_verdict": "Moderate (phase 2 RCTs; development stopped Apr 2025 over liver-injury case; not a peptide).", "card_note": "Varies by use, see page", "regulatory_status": "Never approved; development discontinued · not on the 503A/503B lists or FDA's safety-risk page · not named on WADA's 2026 list", "pmids": "34127852;35647711;37213102;40539310;41450584", "nct_ids": "NCT03985293;NCT04707313", "search_aliases": "pf-06882961 oral non-peptide glp-1 agonist", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/danuglipron/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "dapiglutide", "title": "Dapiglutide", "full_title": "Dapiglutide: What the evidence says", "kind": "compound", "focus_area": "Metabolic & weight", "focus_area_key": "metabolic", "evidence_tier": "Very limited", "card_verdict": "Very limited (one small phase 1 trial showed no significant weight loss; program paused Nov 2025).", "card_note": "", "regulatory_status": "Not FDA-approved (no Drugs@FDA record) · Program paused by Zealand (Nov 2025) · EU, Japan, China: [UNVERIFIED] not checked against EMA, PMDA or NMPA · WADA: not named; S0 (unapproved substances) likely applies", "pmids": "34705281;35580981;41768273", "nct_ids": "NCT05788601", "search_aliases": "zp7570 glp-1 glp-2 dual agonist", "last_checked": "2026-10-25", "url": "https://openpeptideproject.org/library/dapiglutide/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "daptomycin", "title": "Daptomycin (Cubicin)", "full_title": "Daptomycin (Cubicin): What the evidence says", "kind": "compound", "focus_area": "Immune & antimicrobial", "focus_area_key": "immune", "evidence_tier": "Strong", "card_verdict": "Strong (FDA-approved lipopeptide antibiotic for bloodstream and skin infections).", "card_note": "FDA-approved lipopeptide antibiotic", "regulatory_status": "FDA-approved · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · not named by WADA", "pmids": "16914701", "nct_ids": "", "search_aliases": "cubicin cubicin rf lipopeptide antibiotic mrsa bacteremia", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/daptomycin/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "dasiglucagon", "title": "Dasiglucagon (Zegalogue)", "full_title": "Dasiglucagon (Zegalogue): What the evidence says", "kind": "compound", "focus_area": "Metabolic & weight", "focus_area_key": "metabolic", "evidence_tier": "Strong", "card_verdict": "Strong (FDA-approved rescue drug for severe hypoglycemia).", "card_note": "Prescription emergency medicine", "regulatory_status": "FDA-approved (NDA 214231) · not approved for congenital hyperinsulinism · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · not named by WADA", "pmids": "35239971;37930757;39584500", "nct_ids": "NCT04172441", "search_aliases": "zegalogue zp4207 glucagon analog hypoglycemia", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/dasiglucagon/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "davunetide", "title": "Davunetide (NAP, AL-108)", "full_title": "Davunetide (NAP, AL-108): What the evidence says", "kind": "compound", "focus_area": "Brain, mood & sleep", "focus_area_key": "neuro", "evidence_tier": "No human data", "card_verdict": "Tested, not shown (progressive supranuclear palsy Phase 2/3 & schizophrenia RCTs).", "card_note": "Development stopped, see page", "regulatory_status": "Never approved · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · WADA: not named", "pmids": "10037502;22169248;23971871;24873720;37845254;39358355", "nct_ids": "NCT00422981;NCT01110720", "search_aliases": "", "last_checked": "2026-10-26", "url": "https://openpeptideproject.org/library/davunetide/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "decapeptide-12", "title": "Decapeptide-12 (Lumixyl)", "full_title": "Decapeptide-12 (Lumixyl): What the evidence says", "kind": "compound", "focus_area": "Skin, hair & aging", "focus_area_key": "skin", "evidence_tier": "Very limited", "card_verdict": "Very limited (tiny studies; no head-to-head trial with hydroquinone).", "card_note": "Cosmetic skin-lightening peptide", "regulatory_status": "Cosmetic ingredient; not FDA-approved · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · not named by WADA", "pmids": "19440221;19663110;22401652;22527440;23839199", "nct_ids": "", "search_aliases": "lumixyl yrserdfrll tyrosinase inhibitor hyperpigmentation melasma brightening cosmetic peptide", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/decapeptide-12/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "degarelix", "title": "Degarelix (Firmagon)", "full_title": "Degarelix (Firmagon): What the evidence says", "kind": "compound", "focus_area": "Hormones & fertility", "focus_area_key": "endocrine", "evidence_tier": "Strong", "card_verdict": "Strong (FDA-approved for advanced prostate cancer).", "card_note": "Varies by use, see page", "regulatory_status": "FDA-approved (NDA 022201) · not on the 503A/503B lists or FDA's safety-risk page · WADA 2026 S2.2.1 names GnRH agonists (males); degarelix, an antagonist, is not named", "pmids": "19035858;24661333;34459214", "nct_ids": "NCT02663908", "search_aliases": "firmagon gnrh antagonist prostate cancer", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/degarelix/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "desmopressin", "title": "Desmopressin", "full_title": "Desmopressin: What the evidence says", "kind": "compound", "focus_area": "Hormones & fertility", "focus_area_key": "endocrine", "evidence_tier": "Strong", "card_verdict": "Strong (diabetes insipidus, nocturia, bleeding disorders) · \"Nootropic\" sprays: No human data · Banned in sport.", "card_note": "Can cause dangerously low sodium, see page.", "regulatory_status": "FDA-approved: DDAVP NDA 018938 (injection) and 019955 (tablets), Stimate NDA 020355, generics · boxed hyponatremia warning (injection) · WADA: prohibited at all times (S5 masking agent, named)", "pmids": "67283;23454402", "nct_ids": "", "search_aliases": "ddavp minirin stimate nocdurna vasopressin adh", "last_checked": "2026-10-25", "url": "https://openpeptideproject.org/library/desmopressin/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "difelikefalin", "title": "Difelikefalin (Korsuva, CR845)", "full_title": "Difelikefalin (Korsuva, CR845): What the evidence says", "kind": "compound", "focus_area": "Brain, mood & sleep", "focus_area_key": "neuro", "evidence_tier": "Strong", "card_verdict": "Strong (FDA-approved for dialysis-related itching).", "card_note": "FDA-approved peripheral kappa-opioid peptide", "regulatory_status": "FDA-approved · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · not named by WADA", "pmids": "31702883;32405581", "nct_ids": "", "search_aliases": "korsuva cr845 kappa opioid pruritus itching dialysis", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/difelikefalin/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "dihexa", "title": "Dihexa", "full_title": "Dihexa: What the evidence says", "kind": "compound", "focus_area": "Brain, mood & sleep", "focus_area_key": "neuro", "evidence_tier": "No human data", "card_verdict": "No human data (rat/mouse cognitive studies only; key mechanism paper retracted in 2025).", "card_note": "", "regulatory_status": "Not FDA-approved (no Drugs@FDA record) · Not approved anywhere in the world · WADA 2026: not named; S0 (non-approved substances) or S2.3 (HGF/growth factor modulators) applies", "pmids": "23055539;25187433;34551987;34551989;34827486;40312093", "nct_ids": "", "search_aliases": "", "last_checked": "2026-10-25", "url": "https://openpeptideproject.org/library/dihexa/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "dsip", "title": "DSIP (delta sleep-inducing peptide)", "full_title": "DSIP (delta sleep-inducing peptide): What the evidence says", "kind": "compound", "focus_area": "Brain, mood & sleep", "focus_area_key": "neuro", "evidence_tier": "Very limited", "card_verdict": "Very limited (chronic insomnia, mixed results; alcohol/opioid withdrawal) · Injected sleep, recovery, longevity: No human data.", "card_note": "Mixed use: insomnia trials conflict, withdrawal data are uncontrolled, and gray-market injected use is untested. See page.", "regulatory_status": "Russia: registered OTC nasal medicine (Deltaran) · US: not FDA-approved; FDA proposed it NOT be added to the 503A list (July 2026), no final decision found as of Oct 26, 2026 · WADA 2026: not named", "pmids": "1299794;3550726;3583493;3622582;6328354;6548969;9617990;9762721;15911358;16539679;19142086;25739189", "nct_ids": "", "search_aliases": "", "last_checked": "2026-10-26", "url": "https://openpeptideproject.org/library/dsip/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "dulaglutide", "title": "Dulaglutide", "full_title": "Dulaglutide: What the evidence says", "kind": "compound", "focus_area": "Metabolic & weight", "focus_area_key": "metabolic", "evidence_tier": "Strong", "card_verdict": "Strong (type 2 diabetes, heart-risk reduction) · Gray-market/compounded: No human data.", "card_note": "Not approved for weight loss; gray-market products are not Trulicity, see page.", "regulatory_status": "FDA-approved: Trulicity BLA 125469 (Sep 18, 2014) · boxed warning · WADA: not named on the 2026 List", "pmids": "24879836;31189511", "nct_ids": "NCT01394952", "search_aliases": "trulicity glp-1 diabetes", "last_checked": "2026-10-25", "url": "https://openpeptideproject.org/library/dulaglutide/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "ecallantide", "title": "Ecallantide (Kalbitor, DX-88)", "full_title": "Ecallantide (Kalbitor, DX-88): What the evidence says", "kind": "compound", "focus_area": "Immune & antimicrobial", "focus_area_key": "immune", "evidence_tier": "Strong", "card_verdict": "Strong (FDA-approved for acute hereditary angioedema attacks).", "card_note": "FDA-approved kallikrein-inhibitor protein for HAE attacks", "regulatory_status": "FDA-approved · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · not named by WADA", "pmids": "20568386;20818887;21481442", "nct_ids": "NCT00262080;NCT00457015", "search_aliases": "kalbitor dx-88 plasma kallikrein inhibitor hereditary angioedema hae edema3 edema4", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/ecallantide/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "ecnoglutide", "title": "Ecnoglutide (XW003)", "full_title": "Ecnoglutide (XW003): What the evidence says", "kind": "compound", "focus_area": "Metabolic & weight", "focus_area_key": "metabolic", "evidence_tier": "Moderate", "card_verdict": "Moderate (phase 3 RCTs, all in China; approved in China, not in the US).", "card_note": "Weekly GLP-1 injection approved in China; not FDA-approved", "regulatory_status": "Approved in China ; not FDA-approved · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · not named by WADA", "pmids": "37364710;39333121;40555243;41501026;42412371", "nct_ids": "NCT04389775;NCT05813795", "search_aliases": "xw003 xw-003 camp-biased glp-1 receptor agonist weight loss obesity diabetes eecoh", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/ecnoglutide/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "efinopegdutide", "title": "Efinopegdutide", "full_title": "Efinopegdutide: What the evidence says", "kind": "compound", "focus_area": "Metabolic & weight", "focus_area_key": "metabolic", "evidence_tier": "Limited", "card_verdict": "Limited (liver fat and weight) · Type 2 diabetes: Very limited (mixed results).", "card_note": "Varies by use, see page", "regulatory_status": "Not FDA-approved (no Drugs@FDA record) · EU, Japan, China: [UNVERIFIED] not checked against EMA, PMDA or NMPA · WADA: not named; S0 (unapproved substances) likely applies", "pmids": "33475251;33475255;37355043", "nct_ids": "NCT04944992;NCT05877547", "search_aliases": "mk-6024 hm12525a glp-1 glucagon mash", "last_checked": "2026-10-25", "url": "https://openpeptideproject.org/library/efinopegdutide/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "efpeglenatide", "title": "Efpeglenatide (HM11260C, Eppe)", "full_title": "Efpeglenatide (HM11260C, Eppe): What the evidence says", "kind": "compound", "focus_area": "Metabolic & weight", "focus_area_key": "metabolic", "evidence_tier": "Moderate", "card_verdict": "Moderate (phase 3 CV/renal outcomes & obesity RCTs; approved in South Korea; not FDA-approved).", "card_note": "Not FDA-approved", "regulatory_status": "Not FDA-approved · approved in South Korea, Oct 2026 · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · not named by WADA", "pmids": "34215025", "nct_ids": "NCT03496298", "search_aliases": "hm11260c eppe long-acting exendin-4 glp-1", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/efpeglenatide/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "efruxifermin", "title": "Efruxifermin (EFX, AKR-001)", "full_title": "Efruxifermin (EFX, AKR-001): What the evidence says", "kind": "compound", "focus_area": "Metabolic & weight", "focus_area_key": "metabolic", "evidence_tier": "Moderate", "card_verdict": "Moderate (phase 2b MASH fibrosis, investigational).", "card_note": "Varies by use, see page", "regulatory_status": "Investigational · biologic, not on the 503A/503B lists or FDA's safety-risk page · WADA 2026 S2.3 lists fibroblast growth factors (FGFs); ⚠️ [UNVERIFIED] whether an FGF21 analogue is covered", "pmids": "34239138;34773249;36644237;40341827;40818852", "nct_ids": "NCT04767529;NCT05039450;NCT06161571;NCT06215716;NCT06528314", "search_aliases": "efx akr-001 fc-fgf21 mash nash fibrosis", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/efruxifermin/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "eloralintide", "title": "Eloralintide", "full_title": "Eloralintide: What the evidence says", "kind": "compound", "focus_area": "Metabolic & weight", "focus_area_key": "metabolic", "evidence_tier": "Moderate", "card_verdict": "Moderate (phase 2 obesity RCT; phase 3 under way; investigational).", "card_note": "Investigational; phase 3 under way", "regulatory_status": "Investigational, not FDA-approved · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · not named on WADA's 2026 list", "pmids": "41109426;41207310;41559929", "nct_ids": "NCT06230523;NCT06916065;NCT07282600;NCT07321886;NCT07881432", "search_aliases": "ly3841136 selective amylin agonist", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/eloralintide/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "endoluten", "title": "Endoluten (pineal peptide complex)", "full_title": "Endoluten (pineal peptide complex): What the evidence says", "kind": "compound", "focus_area": "Longevity & bioregulators", "focus_area_key": "longevity", "evidence_tier": "No human data", "card_verdict": "No human data (no indexed peer-reviewed clinical trial found).", "card_note": "Russian oral tissue-extract supplement; no indexed trials", "regulatory_status": "Not FDA-approved · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · not named by WADA", "pmids": "12374906", "nct_ids": "", "search_aliases": "a-8 pineal cytomax khavinson", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/endoluten/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "enfuvirtide", "title": "Enfuvirtide (Fuzeon, T-20)", "full_title": "Enfuvirtide (Fuzeon, T-20): What the evidence says", "kind": "compound", "focus_area": "Immune & antimicrobial", "focus_area_key": "immune", "evidence_tier": "Strong", "card_verdict": "Strong (FDA-approved HIV-1 fusion inhibitor; now discontinued in US).", "card_note": "FDA-approved HIV fusion inhibitor; US product discontinued", "regulatory_status": "FDA-approved, discontinued · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · not named by WADA", "pmids": "12637625;12773645", "nct_ids": "", "search_aliases": "fuzeon t-20 gp41 fusion inhibitor hiv", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/enfuvirtide/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "enlicitide", "title": "Enlicitide (Lipfendra, MK-0616)", "full_title": "Enlicitide (Lipfendra, MK-0616): What the evidence says", "kind": "compound", "focus_area": "Heart, blood & gut", "focus_area_key": "cardio", "evidence_tier": "Strong", "card_verdict": "Strong (FDA-approved oral PCSK9 inhibitor for LDL lowering).", "card_note": "FDA-approved oral macrocyclic peptide for LDL cholesterol", "regulatory_status": "FDA-approved · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · not named by WADA", "pmids": "36889610;41879224;42017875", "nct_ids": "NCT05261126;NCT05952856;NCT06450366", "search_aliases": "lipfendra mk-0616 mk0616 enlicitide decanoate oral pcsk9 inhibitor macrocyclic peptide ldl cholesterol coralreef", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/enlicitide/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "enobosarm", "title": "Enobosarm (ostarine, MK-2866, GTx-024)", "full_title": "Enobosarm (ostarine, MK-2866, GTx-024): What the evidence says", "kind": "compound", "focus_area": "Muscle, bone & recovery", "focus_area_key": "muscle", "evidence_tier": "Moderate", "card_verdict": "Moderate (lean mass in trials; no approval; not a peptide).", "card_note": "Investigational SARM pill; not a peptide", "regulatory_status": "Not FDA-approved · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · named on WADA S1.2", "pmids": "23499390;27138015", "nct_ids": "NCT01355497;NCT06282458", "search_aliases": "ostarine mk-2866 gtx-024 s-22 sarm muscle cachexia", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/enobosarm/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "epitalon", "title": "Epitalon", "full_title": "Epitalon: What the evidence says", "kind": "compound", "focus_area": "Longevity & bioregulators", "focus_area_key": "longevity", "evidence_tier": "Very limited", "card_verdict": "Very limited (sleep and melatonin) · Telomeres, longevity, and anti-aging in people: No human data.", "card_note": "Varies by use, see page", "regulatory_status": "Russia: no listing found ⚠️ · US: not FDA-approved; listed by FDA as nominated but withdrawn (formerly 503A Category 2), not on the bulks list; FDA advisers reportedly backed compounding in July 2026 against FDA staff advice, no final FDA decision · WADA 2026: not named; S0 likely applies if no government has approved it", "pmids": "12809170;12937682;14501183;14523363;14647006;15085253;15452611;15455129;15909815;17426848;17969590;18856211;25535022;40141333;40908429;41240216;42752426", "nct_ids": "", "search_aliases": "epithalon aedg ala-glu-asp-gly pineal tetrapeptide khavinson", "last_checked": "2026-10-15", "url": "https://openpeptideproject.org/library/epitalon/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "epithalamin", "title": "Epithalamin", "full_title": "Epithalamin: What the evidence says", "kind": "compound", "focus_area": "Longevity & bioregulators", "focus_area_key": "longevity", "evidence_tier": "Very limited", "card_verdict": "Very limited (aging, developer-led Russian cohorts).", "card_note": "Gray-market \"epithalamin\" or \"epitalon\" vials are a different product from the Russian extract in these studies.", "regulatory_status": "Not FDA-approved (no Drugs@FDA record) · Russia: reported as registered in GRLS [UNVERIFIED] · WADA 2026: not named; S0 depends on Russian registration status [UNVERIFIED]", "pmids": "9701766;14523363;15452611;40141333", "nct_ids": "", "search_aliases": "", "last_checked": "2026-10-25", "url": "https://openpeptideproject.org/library/epithalamin/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "etelcalcetide", "title": "Etelcalcetide (Parsabiv, AMG 416)", "full_title": "Etelcalcetide (Parsabiv, AMG 416): What the evidence says", "kind": "compound", "focus_area": "Hormones & fertility", "focus_area_key": "endocrine", "evidence_tier": "Strong", "card_verdict": "Strong (FDA-approved for dialysis secondary hyperparathyroidism).", "card_note": "FDA-approved IV calcimimetic peptide", "regulatory_status": "FDA-approved · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · not named by WADA", "pmids": "28097356", "nct_ids": "", "search_aliases": "parsabiv amg 416 velcalcetide calcimimetic hyperparathyroidism dialysis", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/etelcalcetide/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "exenatide", "title": "Exenatide", "full_title": "Exenatide: What the evidence says", "kind": "compound", "focus_area": "Metabolic & weight", "focus_area_key": "metabolic", "evidence_tier": "Strong", "card_verdict": "Strong (type 2 diabetes) · Parkinson's: mixed results, phase 3 negative · Gray-market vials: No human data.", "card_note": "Gray-market \"exendin-4\" is not the approved product, see page.", "regulatory_status": "FDA-approved: Byetta NDA 021773, Bydureon NDA 022200, Bydureon BCise NDA 209210; Drugs@FDA lists all three as Discontinued · generic exenatide approved (Amneal ANDA 206697, Nov 19, 2024) · WADA: not named on the 2026 List", "pmids": "15855572;28781108;28910237;39919773", "nct_ids": "NCT01144338;NCT01971242;NCT04232969", "search_aliases": "byetta bydureon exendin-4 glp-1 diabetes", "last_checked": "2026-10-25", "url": "https://openpeptideproject.org/library/exenatide/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "follistatin", "title": "Follistatin (FS344)", "full_title": "Follistatin (FS344): What the evidence says", "kind": "compound", "focus_area": "Muscle, bone & recovery", "focus_area_key": "muscle", "evidence_tier": "Limited", "card_verdict": "Limited (AAV gene therapy in muscle disease) · Injected follistatin peptide or vials: No human data.", "card_note": "Human data is viral gene therapy, not injected peptide vials. Varies by use, see page.", "regulatory_status": "Never approved · Not on FDA 503A or 503B bulk lists · WADA 2026: prohibited at all times (S4.3, myostatin-binding proteins)", "pmids": "20368179;25322757;27858738;28279643;28927986;31758732;34721976", "nct_ids": "NCT01519349;NCT02354781;NCT06411366;NCT07285629;NCT07443826", "search_aliases": "", "last_checked": "2026-10-26", "url": "https://openpeptideproject.org/library/follistatin/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "foxo4-dri", "title": "FOXO4-DRI", "full_title": "FOXO4-DRI: What the evidence says", "kind": "compound", "focus_area": "Longevity & bioregulators", "focus_area_key": "longevity", "evidence_tier": "No human data", "card_verdict": "No human data (senolytic anti-aging claims rest on mouse and dish studies only).", "card_note": "", "regulatory_status": "Not FDA-approved (no Drugs@FDA record) · Not approved anywhere in the world · WADA 2026: S0 (unapproved substances) applies", "pmids": "28340339;39994346", "nct_ids": "", "search_aliases": "", "last_checked": "2026-10-25", "url": "https://openpeptideproject.org/library/foxo4-dri/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "gallium-ga-68-dotatate", "title": "Gallium Ga 68 dotatate (Netspot, 68Ga-DOTATATE)", "full_title": "Gallium Ga 68 dotatate (Netspot, 68Ga-DOTATATE): What the evidence says", "kind": "compound", "focus_area": "Hormones & fertility", "focus_area_key": "endocrine", "evidence_tier": "Strong", "card_verdict": "Strong (FDA-approved PET imaging agent for neuroendocrine tumors).", "card_note": "FDA-approved diagnostic peptide for PET scans", "regulatory_status": "FDA-approved · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · not named by WADA", "pmids": "26712231;26769864", "nct_ids": "", "search_aliases": "netspot 68ga-dotatate ga-68 dotatate somakit toc dota-octreotate pet imaging neuroendocrine tumors sstr", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/gallium-ga-68-dotatate/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "ganirelix", "title": "Ganirelix (Antagon / Orgalutran / Fyremadel)", "full_title": "Ganirelix (Antagon / Orgalutran / Fyremadel): What the evidence says", "kind": "compound", "focus_area": "Hormones & fertility", "focus_area_key": "endocrine", "evidence_tier": "Strong", "card_verdict": "Strong (FDA-approved for IVF ovulation prevention) · Off-label uses: No human data.", "card_note": "Prescription fertility drug", "regulatory_status": "FDA-approved (NDA 021057) · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · not named by WADA", "pmids": "10875855;11163814;11278211", "nct_ids": "", "search_aliases": "antagon orgalutran fyremadel gnrh antagonist ivf fertility", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/ganirelix/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "garetosmab", "title": "Garetosmab (Pasatru, REGN2477)", "full_title": "Garetosmab (Pasatru, REGN2477): What the evidence says", "kind": "compound", "focus_area": "Muscle, bone & recovery", "focus_area_key": "muscle", "evidence_tier": "Strong", "card_verdict": "Strong (FDA-approved for FOP; phase 3 OPTIMA).", "card_note": "FDA-approved FOP antibody; activin A blocker", "regulatory_status": "FDA-approved · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · banned by WADA S4.3", "pmids": "42798232;42805227", "nct_ids": "NCT05394116;NCT06299098", "search_aliases": "pasatru regn2477 activin a fop fibrodysplasia ossificans progressiva", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/garetosmab/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "gepon", "title": "Gepon (Human Ezrin Peptide 1, HEP-1)", "full_title": "Gepon (Human Ezrin Peptide 1, HEP-1): What the evidence says", "kind": "compound", "focus_area": "Immune & antimicrobial", "focus_area_key": "immune", "evidence_tier": "Very limited", "card_verdict": "Very limited (developer reviews and Russian clinic reports only; not FDA-approved).", "card_note": "Ezrin-derived peptide registered in Russia; not a US drug", "regulatory_status": "Not FDA-approved · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · not named by WADA", "pmids": "28668507;32621844;34769119", "nct_ids": "NCT04627233", "search_aliases": "hep-1 human ezrin peptide 324-337", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/gepon/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "ghk-cu", "title": "GHK-Cu", "full_title": "GHK-Cu: What the evidence says", "kind": "compound", "focus_area": "Skin, hair & aging", "focus_area_key": "skin", "evidence_tier": "Very limited", "card_verdict": "Very limited (topical skin creams, mixed results) · Injected use: No human data.", "card_note": "Varies by use, see page", "regulatory_status": "Not FDA-approved as a drug · not named on WADA list", "pmids": "8227353;16847171;18644225;23744835;25731775;29986520", "nct_ids": "", "search_aliases": "copper tripeptide-1 copper peptide cu-ghk skin hair wound", "last_checked": "2026-10-15", "url": "https://openpeptideproject.org/library/ghk-cu/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "ghrp-2", "title": "GHRP-2", "full_title": "GHRP-2: What the evidence says", "kind": "compound", "focus_area": "Hormones & fertility", "focus_area_key": "endocrine", "evidence_tier": "Moderate", "card_verdict": "Moderate (diagnostic GH test, Japan) · Short-term GH release: Limited · Muscle, fat loss, anti-aging: No human data.", "card_note": "Varies by use, see page", "regulatory_status": "Not FDA-approved · 503A Category 3 · 503B Category 2 (injectable and nasal) and Category 1 (other routes) · WADA 2026: prohibited at all times (S2.2.4)", "pmids": "15230633;15645295;15646370;15699539;20878896;25809000;28830317;29973439;30051972;31758732;31776295;37295337", "nct_ids": "", "search_aliases": "", "last_checked": "2026-10-26", "url": "https://openpeptideproject.org/library/ghrp-2/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "ghrp-6", "title": "GHRP-6", "full_title": "GHRP-6: What the evidence says", "kind": "compound", "focus_area": "Hormones & fertility", "focus_area_key": "endocrine", "evidence_tier": "Moderate", "card_verdict": "Moderate (IV diagnostic test for GH deficiency) · Short-term GH release: Limited · Muscle, fat loss, healing, anti-aging: No human data.", "card_note": "Varies by use, see page", "regulatory_status": "Never approved · FDA 503B Category 2 \"significant safety risks,\" Sept 29, 2023 · FDA 503A Category 3 (nominated without adequate support) · WADA 2026: prohibited at all times (S2.2.4)", "pmids": "7581965;7617137;7903313;7952160;8374685;8435889;10336729;11030292;11980622;14725679;16417467;16712669;19946832;23099431;27200188;33272786;40024561", "nct_ids": "", "search_aliases": "", "last_checked": "2026-10-26", "url": "https://openpeptideproject.org/library/ghrp-6/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "glepaglutide", "title": "Glepaglutide (ZP1848, Zeydovio)", "full_title": "Glepaglutide (ZP1848, Zeydovio): What the evidence says", "kind": "compound", "focus_area": "Heart, blood & gut", "focus_area_key": "cardio", "evidence_tier": "Moderate", "card_verdict": "Moderate (phase 3 short bowel syndrome RCT; EU CHMP positive; not FDA-approved).", "card_note": "Investigational in the US", "regulatory_status": "Not FDA-approved (CRL 2024) · positive EU CHMP opinion 2026 · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · not named by WADA", "pmids": "30880176;39708985", "nct_ids": "NCT03690206;NCT07197944", "search_aliases": "zp1848 zeydovio glp-2 short bowel syndrome", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/glepaglutide/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "glow", "title": "GLOW blend", "full_title": "GLOW blend: What the evidence says", "kind": "compound", "focus_area": "Skin, hair & aging", "focus_area_key": "skin", "evidence_tier": "No human data", "card_verdict": "No human data (BPC-157 + TB-500 + GHK-Cu blend never studied together in humans or animals).", "card_note": "", "regulatory_status": "Not FDA-approved · on FDA's \"nominated but withdrawn\" list (formerly Category 2): BPC-157, TB-500, and GHK-Cu (injectable) · WADA 2026: BPC-157 S0, TB-500 S2.3, prohibited at all times", "pmids": "22856429;22962027;27847966;29986520;32334036;38382158;42757290", "nct_ids": "NCT07803250", "search_aliases": "", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/glow/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "glucagon", "title": "Glucagon (Gvoke, Baqsimi, generics)", "full_title": "Glucagon (Gvoke, Baqsimi, generics): What the evidence says", "kind": "compound", "focus_area": "Metabolic & weight", "focus_area_key": "metabolic", "evidence_tier": "Strong", "card_verdict": "Strong (FDA-approved rescue drug for severe hypoglycemia).", "card_note": "FDA-approved hormone for severe low blood sugar", "regulatory_status": "FDA-approved · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · not named by WADA", "pmids": "26884472;32025860;37366315;40421736;42253238", "nct_ids": "", "search_aliases": "gvoke baqsimi glucagen emergency kit severe hypoglycemia gcgr", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/glucagon/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "glutathione", "title": "Glutathione", "full_title": "Glutathione: What the evidence says", "kind": "compound", "focus_area": "Longevity & bioregulators", "focus_area_key": "longevity", "evidence_tier": "Limited", "card_verdict": "Limited (chemo nerve damage: mixed results; Parkinson's and cystic fibrosis: no benefit) · Skin lightening: Very limited · IV detox / anti-aging: No human data.", "card_note": "Mixed use: a supplement and skin ingredient that is also sold as IV drips; no IV use is approved. See page.", "regulatory_status": "US: not approved as a drug on its own (an ingredient of BSS Plus eye-irrigation solution, NDA 018469) · sold as a dietary supplement · WADA 2026: not a banned substance, but IV infusions over 100 mL per 12 hours are banned (M2.2)", "pmids": "7799029;8938817;9261526;12177109;19230029;20524875;23631796;24619793;25378941;26148180;26230671;27088927;28436395;28490897;28789631;29445569;42751591", "nct_ids": "NCT00506688", "search_aliases": "gsh reduced l-glutathione antioxidant", "last_checked": "2026-10-26", "url": "https://openpeptideproject.org/library/glutathione/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "gonadorelin", "title": "Gonadorelin", "full_title": "Gonadorelin: What the evidence says", "kind": "compound", "focus_area": "Hormones & fertility", "focus_area_key": "endocrine", "evidence_tier": "Limited", "card_verdict": "Limited (pump treatment for congenital hypogonadotropic hypogonadism) · Bodybuilding/PCT use: No human data.", "card_note": "Varies by use, see page", "regulatory_status": "Historical FDA approvals discontinued (Factrel NDA 018123, Lutrepulse; openFDA Oct 24, 2026) · Not approved for TRT testicular maintenance · WADA 2026: prohibited at all times in males (S2.2.1, named)", "pmids": "26197466;30569789", "nct_ids": "", "search_aliases": "factrel lutrepulse lhrh gnrh", "last_checked": "2026-10-25", "url": "https://openpeptideproject.org/library/gonadorelin/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "goserelin", "title": "Goserelin (Zoladex)", "full_title": "Goserelin (Zoladex): What the evidence says", "kind": "compound", "focus_area": "Hormones & fertility", "focus_area_key": "endocrine", "evidence_tier": "Strong", "card_verdict": "Strong (FDA-approved for prostate and breast cancer and endometriosis).", "card_note": "FDA-approved GnRH-agonist implant", "regulatory_status": "FDA-approved · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · prohibited in male athletes (WADA S2.2.1)", "pmids": "19821328;20933466;21325445", "nct_ids": "", "search_aliases": "zoladex ici 118630 gnrh lhrh agonist implant prostate cancer breast cancer endometriosis", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/goserelin/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "gotratix", "title": "Gotratix (skeletal muscle peptide complex)", "full_title": "Gotratix (skeletal muscle peptide complex): What the evidence says", "kind": "compound", "focus_area": "Longevity & bioregulators", "focus_area_key": "longevity", "evidence_tier": "No human data", "card_verdict": "No human data (no indexed peer-reviewed clinical trial found).", "card_note": "Russian oral tissue-extract supplement; no indexed trials", "regulatory_status": "Not FDA-approved · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · not named by WADA", "pmids": "12374906", "nct_ids": "", "search_aliases": "a-18 muscle cytomax khavinson", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/gotratix/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "gsbr-1290", "title": "GSBR-1290 (aleniglipron)", "full_title": "GSBR-1290 (aleniglipron): What the evidence says", "kind": "compound", "focus_area": "Metabolic & weight", "focus_area_key": "metabolic", "evidence_tier": "Limited", "card_verdict": "Limited (one phase 2b RCT; phase 3 under way; not a peptide).", "card_note": "Investigational daily GLP-1 pill; small molecule", "regulatory_status": "Investigational · not FDA-approved · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · not named on WADA's 2026 list; as a drug not approved anywhere for human use it falls under S0 (non-approved substances)", "pmids": "40191699;42249138", "nct_ids": "NCT05762471;NCT06693843;NCT07654361;NCT07654374", "search_aliases": "aleniglipron gsbr1290 oral small-molecule glp-1 receptor agonist access trial obesity", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/gsbr-1290/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "gw501516", "title": "Cardarine (GW501516)", "full_title": "Cardarine (GW501516): What the evidence says", "kind": "compound", "focus_area": "Metabolic & weight", "focus_area_key": "metabolic", "evidence_tier": "No human data", "card_verdict": "No human data for performance; development stopped over safety.", "card_note": "Not a peptide; prohibited in sport", "regulatory_status": "Never approved; not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · Prohibited at all times, WADA S4.4.1", "pmids": "17110604;18024853;18674809;21318167;22814748;32298044", "nct_ids": "", "search_aliases": "cardarine gw1516 endurobol ppar-delta agonist", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/gw501516/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "hcg", "title": "hCG (human chorionic gonadotropin)", "full_title": "hCG (human chorionic gonadotropin): What the evidence says", "kind": "compound", "focus_area": "Hormones & fertility", "focus_area_key": "endocrine", "evidence_tier": "Very limited", "card_verdict": "Very limited (post-steroid recovery & weight loss; mixed results) · Labeled fertility & endocrine uses: FDA-approved.", "card_note": "Varies by use, see page", "regulatory_status": "FDA-approved prescription biologic (Pregnyl BLA 017692, Novarel BLA 017067, Ovidrel BLA 021149) · Cannot be compounded under 503A/503B (FDA 2020 biologic transition rule) · WADA 2026: prohibited at all times in males (S2.2.1, named)", "pmids": "8527285;15162244;30569789;37769866;41147237;42644333", "nct_ids": "", "search_aliases": "pregnyl novarel ovidrel chorionic gonadotropin fertility testosterone", "last_checked": "2026-10-25", "url": "https://openpeptideproject.org/library/hcg/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "hexapeptide-11", "title": "Hexapeptide-11 (FVAPFP)", "full_title": "Hexapeptide-11 (FVAPFP): What the evidence says", "kind": "compound", "focus_area": "Skin, hair & aging", "focus_area_key": "skin", "evidence_tier": "Very limited", "card_verdict": "Very limited (mostly lab studies; one small human skin test).", "card_note": "Cosmetic anti-aging peptide from yeast", "regulatory_status": "Cosmetic ingredient; not FDA-approved · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · not named by WADA", "pmids": "23578831;25974626;33849044", "nct_ids": "", "search_aliases": "fvapfp phe-val-ala-pro-phe-pro yeast fermentation hexapeptide 11 skin elasticity cosmetic peptide", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/hexapeptide-11/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "hexarelin", "title": "Hexarelin (examorelin)", "full_title": "Hexarelin (examorelin): What the evidence says", "kind": "compound", "focus_area": "Hormones & fertility", "focus_area_key": "endocrine", "evidence_tier": "Limited", "card_verdict": "Limited (raises growth hormone short-term) · Muscle, fat loss, anti-aging: Very limited or no human data.", "card_note": "Varies by use, see page", "regulatory_status": "Never approved anywhere (no openFDA or EMA entry) · not on FDA's \"significant safety risks\" page · WADA 2026: prohibited at all times (S2.2.4, named as examorelin/hexarelin)", "pmids": "8126144;8766941;9589671;10342360;10469018;10516483;10528131;11888836;11959048;12144941", "nct_ids": "", "search_aliases": "", "last_checked": "2026-10-26", "url": "https://openpeptideproject.org/library/hexarelin/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "histrelin", "title": "Histrelin (Supprelin LA; Vantas discontinued)", "full_title": "Histrelin (Supprelin LA; Vantas discontinued): What the evidence says", "kind": "compound", "focus_area": "Hormones & fertility", "focus_area_key": "endocrine", "evidence_tier": "Moderate", "card_verdict": "Moderate (FDA-approved for precocious puberty; single-arm trials).", "card_note": "FDA-approved GnRH-agonist implant", "regulatory_status": "FDA-approved · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · prohibited in male athletes (WADA S2.2.1)", "pmids": "17327379;21851539", "nct_ids": "", "search_aliases": "supprelin la vantas gnrh lhrh agonist hydrogel implant precocious puberty prostate cancer", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/histrelin/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "human-growth-hormone", "title": "Human growth hormone (somatropin, HGH)", "full_title": "Human growth hormone (somatropin, HGH): What the evidence says", "kind": "compound", "focus_area": "Hormones & fertility", "focus_area_key": "endocrine", "evidence_tier": "Strong", "card_verdict": "Strong for approved medical uses · Anti-aging and sports: not supported.", "card_note": "Varies by use, see page", "regulatory_status": "FDA-approved (prescription biologic) · distributing it for non-approved uses is a federal crime · not on the 503A/503B lists · WADA 2026: prohibited at all times (S2.2.3)", "pmids": "11071481;15126541;17227934;18347346;18940879;21602453;22238382;31180479;32707116;33571362", "nct_ids": "", "search_aliases": "somatropin norditropin genotropin humatrope omnitrope nutropin saizen serostim zomacton hgh", "last_checked": "2026-10-26", "url": "https://openpeptideproject.org/library/human-growth-hormone/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "humanin", "title": "Humanin", "full_title": "Humanin: What the evidence says", "kind": "compound", "focus_area": "Longevity & bioregulators", "focus_area_key": "longevity", "evidence_tier": "No human data", "card_verdict": "No human data (neuroprotection & longevity claims rest on animal and cell studies only).", "card_note": "", "regulatory_status": "Not FDA-approved (no Drugs@FDA record) · Not approved anywhere in the world · WADA 2026: S0 (unapproved substances) applies", "pmids": "11327724;38045183", "nct_ids": "", "search_aliases": "", "last_checked": "2026-10-25", "url": "https://openpeptideproject.org/library/humanin/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "icatibant", "title": "Icatibant (Firazyr)", "full_title": "Icatibant (Firazyr): What the evidence says", "kind": "compound", "focus_area": "Heart, blood & gut", "focus_area_key": "cardio", "evidence_tier": "Strong", "card_verdict": "Strong (FDA-approved for acute hereditary angioedema attacks).", "card_note": "Prescription drug", "regulatory_status": "FDA-approved (NDA 022150) · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · not named by WADA", "pmids": "20818888;22123383;24438203", "nct_ids": "", "search_aliases": "firazyr sajazir hoee-140 bradykinin b2 antagonist hereditary angioedema hae", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/icatibant/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "icotrokinra", "title": "Icotrokinra (Icotyde, JNJ-77242113, JNJ-2113, PN-235)", "full_title": "Icotrokinra (Icotyde, JNJ-77242113, JNJ-2113, PN-235): What the evidence says", "kind": "compound", "focus_area": "Immune & antimicrobial", "focus_area_key": "immune", "evidence_tier": "Strong", "card_verdict": "Strong (FDA-approved daily pill for plaque psoriasis).", "card_note": "FDA-approved oral IL-23 receptor-blocking peptide (Mar 2026)", "regulatory_status": "FDA-approved · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · not named by WADA", "pmids": "38324484;40976249;41191932;41191940;42663861;42874103", "nct_ids": "NCT05223868;NCT06095102;NCT06095115;NCT06143878;NCT06220604", "search_aliases": "icotyde jnj-2113 jnj-77242113 pn-235 pn235 oral il-23 receptor antagonist peptide plaque psoriasis frontier icon", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/icotrokinra/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "igf-1-des", "title": "IGF-1 DES (des(1-3)IGF-1)", "full_title": "IGF-1 DES (des(1-3)IGF-1): What the evidence says", "kind": "compound", "focus_area": "Muscle, bone & recovery", "focus_area_key": "muscle", "evidence_tier": "No human data", "card_verdict": "No human data (muscle-growth & gut claims rest on rat, mouse, and cell studies only).", "card_note": "Cancer-growth signal in animals, see page", "regulatory_status": "Never approved · Not on FDA 503A or 503B bulk lists · WADA 2026: prohibited at all times as an IGF-1 analogue", "pmids": "1928375;1996625;2280209;2539101;8930132;10702797;12875741;33587816", "nct_ids": "", "search_aliases": "", "last_checked": "2026-10-26", "url": "https://openpeptideproject.org/library/igf-1-des/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "igf-1-lr3", "title": "IGF-1 LR3 (Long R3 IGF-1)", "full_title": "IGF-1 LR3 (Long R3 IGF-1): What the evidence says", "kind": "compound", "focus_area": "Muscle, bone & recovery", "focus_area_key": "muscle", "evidence_tier": "No human data", "card_verdict": "No human data (a lab reagent; never tested in people).", "card_note": "Not the approved drug: mecasermin (Increlex) is regular IGF-1 for a rare childhood growth disorder; LR3 is a different, untested molecule. See page.", "regulatory_status": "Never approved anywhere (approved IGF-1 is mecasermin/Increlex, a different molecule) · WADA 2026: prohibited at all times (S2.3, \"IGF-1 and its analogues\")", "pmids": "1378742;15110491;20675162;39610283;39679943", "nct_ids": "", "search_aliases": "", "last_checked": "2026-10-26", "url": "https://openpeptideproject.org/library/igf-1-lr3/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "igf-1-mecasermin", "title": "IGF-1 (mecasermin)", "full_title": "IGF-1 (mecasermin): What the evidence says", "kind": "compound", "focus_area": "Muscle, bone & recovery", "focus_area_key": "muscle", "evidence_tier": "Moderate", "card_verdict": "Moderate (approved for rare childhood IGF-1 deficiency) · Muscle, fat loss, anti-aging: No human data.", "card_note": "Varies by use, see page", "regulatory_status": "FDA-approved (Increlex, BLA 021839) for one rare pediatric use · not on the 503A/503B lists · WADA 2026: prohibited at all times (S2.3)", "pmids": "18481900;19663134;24623853;33434161;37579214", "nct_ids": "", "search_aliases": "increlex mecasermin rhigf-1 growth failure", "last_checked": "2026-10-26", "url": "https://openpeptideproject.org/library/igf-1-mecasermin/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "imunofan", "title": "Imunofan (RDKVYR)", "full_title": "Imunofan (RDKVYR): What the evidence says", "kind": "compound", "focus_area": "Immune & antimicrobial", "focus_area_key": "immune", "evidence_tier": "Very limited", "card_verdict": "Very limited (one small Russian RCT plus lab data; not FDA-approved).", "card_note": "Russian-registered hexapeptide; not approved in US", "regulatory_status": "Not FDA-approved · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · not named by WADA", "pmids": "10377887;20481041;32585846", "nct_ids": "", "search_aliases": "rdkvyr hexapeptide", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/imunofan/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "ipamorelin", "title": "Ipamorelin", "full_title": "Ipamorelin: What the evidence says", "kind": "compound", "focus_area": "Hormones & fertility", "focus_area_key": "endocrine", "evidence_tier": "Very limited", "card_verdict": "Very limited (short-term GH release; post-surgery gut recovery, mixed results) · Muscle, fat loss, recovery, sleep, anti-aging: No human data.", "card_note": "Varies by use, see page", "regulatory_status": "Not FDA-approved · FDA 503B Category 2; also listed as formerly 503A Category 2, nomination withdrawn · WADA 2026: banned at all times (S2.2.4)", "pmids": "9849822;10496658;19289567;25331030;27186127;30136411", "nct_ids": "NCT00672074;NCT01280344", "search_aliases": "", "last_checked": "2026-10-15", "url": "https://openpeptideproject.org/library/ipamorelin/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "ipamorelin-cjc-1295", "title": "Ipamorelin + CJC-1295", "full_title": "Ipamorelin + CJC-1295: What the evidence says", "kind": "compound", "focus_area": "Hormones & fertility", "focus_area_key": "endocrine", "evidence_tier": "No human data", "card_verdict": "No human data (blend never tested; each part only raises GH briefly).", "card_note": "Varies by use, see page", "regulatory_status": "Neither FDA-approved · ipamorelin: FDA 503B Category 2 (Sept 29, 2023) · CJC-1295: nomination withdrawn, still on FDA's safety-risk page · WADA 2026: both prohibited at all times (S2.2.4)", "pmids": "9849822;10496658;15817669;16352683;17018654;25331030;30136411", "nct_ids": "NCT00267527;NCT00672074;NCT01280344", "search_aliases": "", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/ipamorelin-cjc-1295/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "kisspeptin-10", "title": "Kisspeptin-10", "full_title": "Kisspeptin-10: What the evidence says", "kind": "compound", "focus_area": "Hormones & fertility", "focus_area_key": "endocrine", "evidence_tier": "Very limited", "card_verdict": "Very limited (short-term LH & testosterone rise in lab studies) · Libido, fertility, muscle, energy: No human data.", "card_note": "Mixed use: hormone-level studies only; the gray-market uses (libido, fertility, muscle) are untested. See page.", "regulatory_status": "Never approved anywhere · 503A: Category 2 (significant safety risks, since Sept 29, 2023) · 503B: not nominated · WADA 2026: named under S2.2.1 (males)", "pmids": "21632807;21976724;33227799;40215751;42549827", "nct_ids": "NCT03286517;NCT03315325;NCT03771326", "search_aliases": "", "last_checked": "2026-10-26", "url": "https://openpeptideproject.org/library/kisspeptin-10/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "kisspeptin-54", "title": "Kisspeptin-54", "full_title": "Kisspeptin-54: What the evidence says", "kind": "compound", "focus_area": "Hormones & fertility", "focus_area_key": "endocrine", "evidence_tier": "Limited", "card_verdict": "Limited (IVF egg-maturation trigger) · Gray-market uses: No human data.", "card_note": "Varies by use, see page", "regulatory_status": "Not FDA-approved (no Drugs@FDA record) · Investigational · WADA 2026: not named; S0 (unapproved substances) likely applies", "pmids": "25036713;26192876;28854728;33196464", "nct_ids": "", "search_aliases": "", "last_checked": "2026-10-25", "url": "https://openpeptideproject.org/library/kisspeptin-54/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "klow", "title": "KLOW blend", "full_title": "KLOW blend: What the evidence says", "kind": "compound", "focus_area": "Skin, hair & aging", "focus_area_key": "skin", "evidence_tier": "No human data", "card_verdict": "No human data (4-peptide blend of BPC-157, TB-500, GHK-Cu & KPV never studied together in humans or animals).", "card_note": "", "regulatory_status": "Not FDA-approved · contains WADA-banned components (BPC-157, TB-500)", "pmids": "18061177;18092346", "nct_ids": "", "search_aliases": "", "last_checked": "2026-10-15", "url": "https://openpeptideproject.org/library/klow/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "kpv", "title": "KPV", "full_title": "KPV: What the evidence says", "kind": "compound", "focus_area": "Immune & antimicrobial", "focus_area_key": "immune", "evidence_tier": "No human data", "card_verdict": "No human data (gut inflammation & skin claims rest on mouse colitis and cell studies only).", "card_note": "Varies by use, see page", "regulatory_status": "Not FDA-approved · on FDA's list of substances previously in Category 2 whose nominations were withdrawn · not on the 503A or 503B bulks lists · WADA 2026: not named; likely covered by S0, unconfirmed by WADA", "pmids": "16965771;18061177;18092346;19909746;26132941;27458604;28143741;40073467", "nct_ids": "NCT05466890", "search_aliases": "", "last_checked": "2026-10-15", "url": "https://openpeptideproject.org/library/kpv/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "kyotorphin", "title": "Kyotorphin (L-Tyr-L-Arg)", "full_title": "Kyotorphin (L-Tyr-L-Arg): What the evidence says", "kind": "compound", "focus_area": "Brain, mood & sleep", "focus_area_key": "neuro", "evidence_tier": "No human data", "card_verdict": "No human data (endogenous brain dipeptide; animal data only).", "card_note": "Endogenous research dipeptide; not a drug", "regulatory_status": "Not FDA-approved · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · not named by WADA", "pmids": "228202;436940;7254487;25363470;35047919", "nct_ids": "", "search_aliases": "", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/kyotorphin/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "lanreotide", "title": "Lanreotide (Somatuline Depot)", "full_title": "Lanreotide (Somatuline Depot): What the evidence says", "kind": "compound", "focus_area": "Hormones & fertility", "focus_area_key": "endocrine", "evidence_tier": "Strong", "card_verdict": "Strong (FDA-approved for acromegaly, GEP-NETs, and carcinoid syndrome).", "card_note": "Prescription drug for rare hormone and tumor conditions", "regulatory_status": "FDA-approved, NDA 022074 · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · not named on WADA's 2026 list", "pmids": "19639415;25014687", "nct_ids": "NCT00353496", "search_aliases": "somatuline depot cipla lanreotide somatostatin", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/lanreotide/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "larazotide", "title": "Larazotide", "full_title": "Larazotide: What the evidence says", "kind": "compound", "focus_area": "Heart, blood & gut", "focus_area_key": "cardio", "evidence_tier": "Limited", "card_verdict": "Limited (celiac disease symptoms, mixed results) · \"Leaky gut\" use: No human data.", "card_note": "Varies by use, see page.", "regulatory_status": "Not FDA-approved (no Drugs@FDA entry found) · WADA: not named; S0 likely applies as an unapproved drug [UNVERIFIED]", "pmids": "22825365;25683116;34339872;40737433", "nct_ids": "NCT03569007", "search_aliases": "", "last_checked": "2026-10-25", "url": "https://openpeptideproject.org/library/larazotide/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "leuphasyl", "title": "Leuphasyl (Pentapeptide-18)", "full_title": "Leuphasyl (Pentapeptide-18): What the evidence says", "kind": "compound", "focus_area": "Skin, hair & aging", "focus_area_key": "skin", "evidence_tier": "Very limited", "card_verdict": "Very limited (cosmetic blend studies only; no isolated human trial; never inject).", "card_note": "Cosmetic ingredient; never inject", "regulatory_status": "Cosmetic ingredient, not a drug · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · not named on WADA's 2026 list", "pmids": "39337562;39459512;41722287;42116636", "nct_ids": "", "search_aliases": "pentapeptide-18 enkephalin cosmetic peptide", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/leuphasyl/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "leuprolide", "title": "Leuprolide", "full_title": "Leuprolide: What the evidence says", "kind": "compound", "focus_area": "Hormones & fertility", "focus_area_key": "endocrine", "evidence_tier": "Strong", "card_verdict": "Strong (prostate cancer, endometriosis, early puberty) · Gray-market: No human data · Banned in male athletes.", "card_note": "Lowers testosterone after an initial surge, see page.", "regulatory_status": "FDA-approved (Lupron Depot NDAs 019732, 020011, 020517, 020708; Lupron Depot-PED NDA 020263; Eligard; Fensolvi; Camcevi; generics) · WADA: prohibited at all times in males (S2.2.1, \"leuprorelin\")", "pmids": "2118858;2503724", "nct_ids": "", "search_aliases": "lupron eligard fensolvi camcevi gnrh agonist", "last_checked": "2026-10-25", "url": "https://openpeptideproject.org/library/leuprolide/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "lgd-4033", "title": "Ligandrol (LGD-4033, VK5211)", "full_title": "Ligandrol (LGD-4033, VK5211): What the evidence says", "kind": "compound", "focus_area": "Muscle, bone & recovery", "focus_area_key": "muscle", "evidence_tier": "Limited", "card_verdict": "Limited (phase 1 lean mass; liver injury risk; not a peptide).", "card_note": "Investigational SARM pill; not a peptide", "regulatory_status": "Not FDA-approved · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · named on WADA S1.2", "pmids": "22459616;32637435;39421081", "nct_ids": "NCT02578095", "search_aliases": "ligandrol vk5211 sarm", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/lgd-4033/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "libidon", "title": "Libidon (prostate peptide complex)", "full_title": "Libidon (prostate peptide complex): What the evidence says", "kind": "compound", "focus_area": "Longevity & bioregulators", "focus_area_key": "longevity", "evidence_tier": "No human data", "card_verdict": "No human data (no indexed peer-reviewed clinical trial found).", "card_note": "Russian oral tissue-extract supplement; no indexed trials", "regulatory_status": "Not FDA-approved · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · not named by WADA", "pmids": "12374906", "nct_ids": "", "search_aliases": "a-16 prostate cytomax khavinson", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/libidon/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "linaclotide", "title": "Linaclotide", "full_title": "Linaclotide: What the evidence says", "kind": "compound", "focus_area": "Heart, blood & gut", "focus_area_key": "cardio", "evidence_tier": "Strong", "card_verdict": "Strong (IBS with constipation, chronic constipation) · Gray-market: No human data.", "card_note": "Never for children under 2, see page.", "regulatory_status": "FDA-approved: Linzess NDA 202811 (Aug 30, 2012); generic ANDAs approved · boxed warning · WADA: not named on the 2026 List", "pmids": "21830967;22986437", "nct_ids": "NCT00730015;NCT00765882", "search_aliases": "linzess constella guanylate cyclase constipation ibs-c", "last_checked": "2026-10-25", "url": "https://openpeptideproject.org/library/linaclotide/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "liraglutide", "title": "Liraglutide", "full_title": "Liraglutide: What the evidence says", "kind": "compound", "focus_area": "Metabolic & weight", "focus_area_key": "metabolic", "evidence_tier": "Strong", "card_verdict": "Strong (approved uses: weight management, type 2 diabetes) · Gray-market vials: No human data.", "card_note": "Gray-market vials are not the approved product, see page.", "regulatory_status": "FDA-approved (Victoza NDA 022341 ; Saxenda NDA 206321 ; labels on DailyMed) · generics approved (ANDAs, first Dec 23, 2024) · WADA: not named on the 2026 List", "pmids": "26132939;27295427;28237263", "nct_ids": "", "search_aliases": "saxenda victoza glp-1 weight loss diabetes", "last_checked": "2026-10-25", "url": "https://openpeptideproject.org/library/liraglutide/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "livagen", "title": "Livagen", "full_title": "Livagen: What the evidence says", "kind": "compound", "focus_area": "Longevity & bioregulators", "focus_area_key": "longevity", "evidence_tier": "No human data", "card_verdict": "No human data (liver & chromatin claims rest on developer-led lab and animal studies only).", "card_note": "Animal/lab data only (developer-led), see page", "regulatory_status": "Not FDA-approved (no Drugs@FDA record) · Russia: registration status [UNVERIFIED] · WADA 2026: not named; S0 (unapproved substances) likely applies", "pmids": "12533768;15085253;16705247;32362099", "nct_ids": "", "search_aliases": "keda lys-glu-asp-ala liver bioregulator khavinson", "last_checked": "2026-10-25", "url": "https://openpeptideproject.org/library/livagen/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "lixisenatide", "title": "Lixisenatide (Adlyxin)", "full_title": "Lixisenatide (Adlyxin): What the evidence says", "kind": "compound", "focus_area": "Metabolic & weight", "focus_area_key": "metabolic", "evidence_tier": "Strong", "card_verdict": "Strong (FDA-approved diabetes drug; now discontinued in US) · Parkinson's: Limited (phase 2).", "card_note": "Prescription GLP-1 drug; US brand discontinued", "regulatory_status": "FDA-approved (BLA 208471), US brand discontinued · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · not named by WADA", "pmids": "26630143;38598572", "nct_ids": "NCT03439943", "search_aliases": "adlyxin lyxumia glp-1 diabetes", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/lixisenatide/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "ll-37", "title": "LL-37 (cathelicidin)", "full_title": "LL-37 (cathelicidin): What the evidence says", "kind": "compound", "focus_area": "Immune & antimicrobial", "focus_area_key": "immune", "evidence_tier": "Limited", "card_verdict": "Limited (leg ulcers, applied to the skin; mixed results) · Injected for immunity, infections, anti-aging: No human data.", "card_note": "Mixed use: tested only on wounds and in tumors; never tested as the injection sold online. See page.", "regulatory_status": "Never approved anywhere (not in openFDA or EMA medicines data) · FDA \"significant safety risks\" page (listed among nominated substances later withdrawn) · WADA 2026: not named; S0 likely applies (our reading)", "pmids": "16716248;17676051;17873860;23246832;25041740;26433491;29665030;34687253;36980564;37480520", "nct_ids": "NCT02225366;NCT04098562", "search_aliases": "", "last_checked": "2026-10-26", "url": "https://openpeptideproject.org/library/ll-37/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "lonapegsomatropin", "title": "Lonapegsomatropin (Skytrofa, TransCon hGH)", "full_title": "Lonapegsomatropin (Skytrofa, TransCon hGH): What the evidence says", "kind": "compound", "focus_area": "Hormones & fertility", "focus_area_key": "endocrine", "evidence_tier": "Strong", "card_verdict": "Strong (FDA-approved weekly growth hormone for children and adults with GH deficiency).", "card_note": "FDA-approved once-weekly growth hormone prodrug", "regulatory_status": "FDA-approved · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · prohibited at all times (WADA S2.2.3)", "pmids": "34272849;41420532", "nct_ids": "NCT02781727;NCT04615273", "search_aliases": "skytrofa lonapegsomatropin-tcgd acp-001 transcon hgh once-weekly growth hormone somatropin prodrug ghd", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/lonapegsomatropin/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "lutetium-lu-177-dotatate", "title": "Lutetium Lu 177 dotatate (Lutathera)", "full_title": "Lutetium Lu 177 dotatate (Lutathera): What the evidence says", "kind": "compound", "focus_area": "Hormones & fertility", "focus_area_key": "endocrine", "evidence_tier": "Strong", "card_verdict": "Strong (FDA-approved radiolabeled peptide for GEP-NETs).", "card_note": "FDA-approved radioactive peptide cancer therapy", "regulatory_status": "FDA-approved · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · not named by WADA", "pmids": "28076709", "nct_ids": "", "search_aliases": "lutathera 177lu-dotatate prrt neuroendocrine tumors gep-net", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/lutetium-lu-177-dotatate/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "macimorelin", "title": "Macimorelin (Macrilen)", "full_title": "Macimorelin (Macrilen): What the evidence says", "kind": "compound", "focus_area": "Hormones & fertility", "focus_area_key": "endocrine", "evidence_tier": "Strong", "card_verdict": "Strong (FDA-approved adult GH deficiency diagnostic test) · Muscle, fat loss, anti-aging: No human data.", "card_note": "Varies by use, see page", "regulatory_status": "FDA-approved diagnostic (NDA 205598) · not on the 503A/503B lists or FDA's safety-risk page · WADA 2026: named under S2.2.4", "pmids": "29860473;33320108;34438400", "nct_ids": "NCT02558829;NCT04786873", "search_aliases": "macrilen aeet-0155 ghrelin agonist adult growth hormone deficiency test", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/macimorelin/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "maritide", "title": "MariTide (Maridebart Cafraglutide)", "full_title": "MariTide (Maridebart Cafraglutide): What the evidence says", "kind": "compound", "focus_area": "Metabolic & weight", "focus_area_key": "metabolic", "evidence_tier": "Limited", "card_verdict": "Limited (monthly injection for weight loss & type 2 diabetes in one phase 2 trial; phase 3 ongoing).", "card_note": "", "regulatory_status": "Not FDA-approved (no Drugs@FDA record) · EU, Japan, China: [UNVERIFIED] not checked against EMA, PMDA or NMPA · WADA: not named; S0 (unapproved substances) likely applies", "pmids": "38316982;40549887;41941715", "nct_ids": "NCT04478708;NCT05669599;NCT06660173;NCT06858839;NCT06858878;NCT06987695;NCT07037433;NCT07037459;NCT07225686;NCT07226765;NCT07441252", "search_aliases": "maridebart cafraglutide amg 133 amg-133 gipr antagonist glp-1", "last_checked": "2026-10-25", "url": "https://openpeptideproject.org/library/maritide/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "matrixyl", "title": "Matrixyl (palmitoyl pentapeptide-4)", "full_title": "Matrixyl (palmitoyl pentapeptide-4): What the evidence says", "kind": "compound", "focus_area": "Skin, hair & aging", "focus_area_key": "skin", "evidence_tier": "Limited", "card_verdict": "Limited (wrinkles, topical cosmetic cream) · Injection or internal use: No human data.", "card_note": "Cosmetic cream ingredient; never tested by injection. Varies by use, see page.", "regulatory_status": "Cosmetic ingredient, not an approved drug · Not on FDA 503A or 503B bulk lists", "pmids": "18492182;19735523;23320752;25033398;30603464;35874243", "nct_ids": "", "search_aliases": "palmitoyl pentapeptide-4 pal-kttks matrixyl original collagen", "last_checked": "2026-10-26", "url": "https://openpeptideproject.org/library/matrixyl/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "matrixyl-3000", "title": "Matrixyl 3000 (palmitoyl tripeptide-1 + palmitoyl tetrapeptide-7)", "full_title": "Matrixyl 3000 (palmitoyl tripeptide-1 + palmitoyl tetrapeptide-7): What the evidence says", "kind": "compound", "focus_area": "Skin, hair & aging", "focus_area_key": "skin", "evidence_tier": "Very limited", "card_verdict": "Very limited (multi-ingredient cosmetic cream study only; never inject).", "card_note": "Topical skincare peptide; not a drug", "regulatory_status": "Cosmetic ingredient, not a drug · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · not named by WADA", "pmids": "18045359;38932444", "nct_ids": "", "search_aliases": "palmitoyl tripeptide-1 palmitoyl tetrapeptide-7 pal-ghk pal-gqpr", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/matrixyl-3000/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "mazdutide", "title": "Mazdutide", "full_title": "Mazdutide: What the evidence says", "kind": "compound", "focus_area": "Metabolic & weight", "focus_area_key": "metabolic", "evidence_tier": "Moderate", "card_verdict": "Moderate (weight loss & type 2 diabetes in Chinese phase 3 trials; approved in China, not FDA-approved).", "card_note": "", "regulatory_status": "Not FDA-approved (no Drugs@FDA record) · Approved in China for weight management, June 2025, and type 2 diabetes, Sept 2025 (confirmed in Adis Drugs and HKEX/ce.cn notices ; `[UNVERIFIED]` direct on nmpa.gov.cn due to host block) · EU, Japan: [UNVERIFIED] not checked against EMA or PMDA · WADA: not named", "pmids": "37943529;38092790;40421736;41028652;41260459;41407859;41407860;42251595;42628555", "nct_ids": "NCT04904913;NCT05606913;NCT05607680;NCT05628311;NCT06124807;NCT06164873", "search_aliases": "ibi362 ly3305677 oxm3 glucagon glp-1 dual agonist", "last_checked": "2026-10-25", "url": "https://openpeptideproject.org/library/mazdutide/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "melanotan-i", "title": "Melanotan I (afamelanotide)", "full_title": "Melanotan I (afamelanotide): What the evidence says", "kind": "compound", "focus_area": "Skin, hair & aging", "focus_area_key": "skin", "evidence_tier": "Moderate", "card_verdict": "Moderate (EPP sun intolerance, FDA-approved implant Scenesse) · Tanning, vitiligo, stroke: Very limited · Sunburn & skin cancer prevention in healthy people: No human data.", "card_note": "Mixed use: the Moderate rating is for the approved EPP implant only; gray-market tanning vials are a different product with very limited data. See page.", "regulatory_status": "Approved (Scenesse implant, EPP): EU Dec 22, 2014; US FDA Oct 8, 2019 · not on FDA 503A/503B lists · WADA 2026: not named", "pmids": "11045725;25230094;25494545;26132941;28266027;28363699;31987791;33721252;37496004;40082741", "nct_ids": "NCT00979745;NCT01430195;NCT01605136;NCT06109649", "search_aliases": "afamelanotide scenesse ndp-alpha-msh epp erythropoietic protoporphyria tanning", "last_checked": "2026-10-26", "url": "https://openpeptideproject.org/library/melanotan-i/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "melanotan-ii", "title": "Melanotan II", "full_title": "Melanotan II: What the evidence says", "kind": "compound", "focus_area": "Skin, hair & aging", "focus_area_key": "skin", "evidence_tier": "Very limited", "card_verdict": "Very limited (erections in men, short-term tanning) · Long-term tanning safety & skin cancer prevention: No human data.", "card_note": "Mixed use: tiny 1990s trials only; never approved, with serious case-report harms. See page.", "regulatory_status": "Never approved anywhere · FDA warning letter (2007) · warnings from UK MHRA, Irish HPRA, Danish Medicines Agency, Australian TGA · on FDA's \"significant safety risks\" page · WADA 2026: not named; S0 applies (our reading)", "pmids": "8637402;9679884;11018622;19174439;19575725;21547334;21564053;22724573;23121206;23537392;23648958;24334249;24355990;26456392;30796078;31953620;33460908", "nct_ids": "", "search_aliases": "mt-2 mt2 melanocortin tanning erectile", "last_checked": "2026-10-26", "url": "https://openpeptideproject.org/library/melanotan-ii/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "methylene-blue", "title": "Methylene blue (methylthioninium chloride, ProvayBlue)", "full_title": "Methylene blue (methylthioninium chloride, ProvayBlue): What the evidence says", "kind": "compound", "focus_area": "Longevity & bioregulators", "focus_area_key": "longevity", "evidence_tier": "Moderate", "card_verdict": "Moderate (FDA-approved IV antidote for acquired methemoglobinemia; other uses lack good evidence; not a peptide).", "card_note": "FDA-approved IV antidote and dye; small molecule", "regulatory_status": "FDA-approved · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · not named by WADA", "pmids": "25018057;27284082;27351678;28686823;30104021;41570392;42355649", "nct_ids": "NCT00214877;NCT01836094;NCT03395223", "search_aliases": "provayblue methylthioninium chloride urolene blue phenothiazine dye methemoglobinemia mitochondrial", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/methylene-blue/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "mgf", "title": "MGF / PEG-MGF (mechano growth factor)", "full_title": "MGF / PEG-MGF (mechano growth factor): What the evidence says", "kind": "compound", "focus_area": "Muscle, bone & recovery", "focus_area_key": "muscle", "evidence_tier": "No human data", "card_verdict": "No human data (muscle-repair claims rest on animal and cell studies only).", "card_note": "", "regulatory_status": "Not FDA-approved (no Drugs@FDA record) · Not approved anywhere in the world · WADA 2026: prohibited at all times (S2.3, \"Mechano growth factors (MGFs)\" named)", "pmids": "23125840;23712705;25466910;26991004", "nct_ids": "", "search_aliases": "", "last_checked": "2026-10-25", "url": "https://openpeptideproject.org/library/mgf/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "mk-677", "title": "MK-677 (ibutamoren)", "full_title": "MK-677 (ibutamoren): What the evidence says", "kind": "compound", "focus_area": "Hormones & fertility", "focus_area_key": "endocrine", "evidence_tier": "Limited", "card_verdict": "Limited (raises GH/IGF-1 and lean mass) · Gray-market use: No human data.", "card_note": "Not a peptide: an oral ghrelin-receptor agonist. Varies by use, see page.", "regulatory_status": "Not FDA-approved (no Drugs@FDA entry found) · WADA: prohibited at all times, S2.2.4", "pmids": "9467542;18981485;19015485;21067829", "nct_ids": "", "search_aliases": "ibutamoren l-163191 oral ghrelin mimetic growth hormone secretagogue", "last_checked": "2026-10-25", "url": "https://openpeptideproject.org/library/mk-677/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "motixafortide", "title": "Motixafortide (Aphexda, BL-8040)", "full_title": "Motixafortide (Aphexda, BL-8040): What the evidence says", "kind": "compound", "focus_area": "Immune & antimicrobial", "focus_area_key": "immune", "evidence_tier": "Strong", "card_verdict": "Strong (FDA-approved stem cell mobilizer for multiple myeloma transplant).", "card_note": "FDA-approved cyclic peptide CXCR4 blocker", "regulatory_status": "FDA-approved · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · not named by WADA", "pmids": "37069359", "nct_ids": "NCT03246529", "search_aliases": "aphexda bl-8040 bkt140 t140 cxcr4 antagonist stem cell mobilization multiple myeloma genesis", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/motixafortide/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "mots-c", "title": "MOTS-c", "full_title": "MOTS-c: What the evidence says", "kind": "compound", "focus_area": "Metabolic & weight", "focus_area_key": "metabolic", "evidence_tier": "No human data", "card_verdict": "No human data (metabolic & exercise claims rest on mouse studies; untested as a human treatment).", "card_note": "Varies by use, see page", "regulatory_status": "Not FDA-approved · WADA-banned (named, S4)", "pmids": "25738459;33473109", "nct_ids": "", "search_aliases": "", "last_checked": "2026-10-15", "url": "https://openpeptideproject.org/library/mots-c/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "myristoyl-pentapeptide-17", "title": "Myristoyl pentapeptide-17", "full_title": "Myristoyl pentapeptide-17: What the evidence says", "kind": "compound", "focus_area": "Skin, hair & aging", "focus_area_key": "skin", "evidence_tier": "Very limited", "card_verdict": "Very limited (safety data from one lash-serum study; no efficacy trial).", "card_note": "Cosmetic lash-serum peptide; no efficacy trial", "regulatory_status": "Cosmetic ingredient; not FDA-approved · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · not named by WADA", "pmids": "22942109;35882176;39479552;42269767", "nct_ids": "", "search_aliases": "sympeptide xlash myr-klakk myristoyl pentapeptide 17 eyelash serum keratin cosmetic peptide", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/myristoyl-pentapeptide-17/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "n-acetyl-semax-selank", "title": "N-Acetyl Semax and N-Acetyl Selank (amidate forms)", "full_title": "N-Acetyl Semax and N-Acetyl Selank (amidate forms): What the evidence says", "kind": "compound", "focus_area": "Brain, mood & sleep", "focus_area_key": "neuro", "evidence_tier": "No human data", "card_verdict": "No human data (zero published studies on the N-acetyl or amidate forms; parent drugs Semax and Selank rated separately).", "card_note": "No published data on these modified forms, see page", "regulatory_status": "Not approved in the US · Semax and selank nominations withdrawn; FDA safety-risk notes still posted · WADA 2026: not named; likely S0 ⚠️", "pmids": "11443939;18454096;25176261;28702721;29798983;31667971;32342318", "nct_ids": "", "search_aliases": "", "last_checked": "2026-10-26", "url": "https://openpeptideproject.org/library/n-acetyl-semax-selank/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "nad-plus", "title": "NAD+", "full_title": "NAD+: What the evidence says", "kind": "compound", "focus_area": "Longevity & bioregulators", "focus_area_key": "longevity", "evidence_tier": "Moderate", "card_verdict": "Moderate (oral NR/NMN raising blood NAD+) · Oral health outcomes: Limited · IV NAD+: Very limited · Injected NAD+: No human data.", "card_note": "Varies by use, see page", "regulatory_status": "NMN and NR: sold as dietary supplements (FDA reversed its 2022 NMN exclusion in Sept 2025) · IV/injectable NAD+: not an FDA-approved drug; compounded under FDA's interim \"Category 1\" policy · not named on WADA's 2026 list, but large IV drips are a banned method for athletes", "pmids": "29599478;29992272;31572171;33888596;35235774;35927255;40275690;41655607;41704678;41915584;42514320", "nct_ids": "", "search_aliases": "nicotinamide adenine dinucleotide nad+ iv longevity", "last_checked": "2026-10-15", "url": "https://openpeptideproject.org/library/nad-plus/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "nafarelin", "title": "Nafarelin (Synarel)", "full_title": "Nafarelin (Synarel): What the evidence says", "kind": "compound", "focus_area": "Hormones & fertility", "focus_area_key": "endocrine", "evidence_tier": "Moderate", "card_verdict": "Moderate (FDA-approved nasal spray; older trials).", "card_note": "FDA-approved GnRH-agonist nasal spray", "regulatory_status": "FDA-approved · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · prohibited in male athletes (WADA S2.2.1)", "pmids": "1531464;16038370", "nct_ids": "", "search_aliases": "synarel rs-94991-298 intranasal gnrh lhrh agonist nasal spray endometriosis precocious puberty", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/nafarelin/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "nesfatin-1", "title": "Nesfatin-1", "full_title": "Nesfatin-1: What the evidence says", "kind": "compound", "focus_area": "Metabolic & weight", "focus_area_key": "metabolic", "evidence_tier": "No human data", "card_verdict": "No human data (blood-level studies only; never tested as a treatment in people).", "card_note": "Natural appetite peptide; never given to people as a treatment", "regulatory_status": "Not approved anywhere · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · not named on WADA's 2026 list; as a drug not approved anywhere for human use it falls under S0 (non-approved substances)", "pmids": "17036007;34566899;38327900;40865110;41623366", "nct_ids": "", "search_aliases": "nucb2 nucleobindin-2 nesfatin1 satiety neuropeptide appetite", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/nesfatin-1/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "nesiritide", "title": "Nesiritide (Natrecor)", "full_title": "Nesiritide (Natrecor): What the evidence says", "kind": "compound", "focus_area": "Heart, blood & gut", "focus_area_key": "cardio", "evidence_tier": "Moderate", "card_verdict": "Moderate (FDA-approved for acute heart failure but neutral in ASCEND-HF; now discontinued).", "card_note": "Discontinued FDA-approved heart-failure peptide", "regulatory_status": "FDA-approved, discontinued · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · not named by WADA", "pmids": "11911755;21732835", "nct_ids": "NCT00475852", "search_aliases": "natrecor bnp recombinant human b-type natriuretic peptide heart failure", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/nesiritide/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "nnz-2591", "title": "NNZ-2591 (cyclo-glycyl-2-allyl proline)", "full_title": "NNZ-2591 (cyclo-glycyl-2-allyl proline): What the evidence says", "kind": "compound", "focus_area": "Brain, mood & sleep", "focus_area_key": "neuro", "evidence_tier": "Very limited", "card_verdict": "Very limited (small open-label trials; phase 3 under way).", "card_note": "Investigational oral cyclic dipeptide from Neuren", "regulatory_status": "Investigational; not FDA-approved · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · not named by WADA", "pmids": "41450730", "nct_ids": "NCT04379869;NCT05011851;NCT05025241;NCT05025332;NCT05879614;NCT07281079;NCT07593391", "search_aliases": "cyclic glycine-proline cgp diketopiperazine phelan-mcdermid angelman pitt hopkins", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/nnz-2591/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "noopept", "title": "Noopept (omberacetam)", "full_title": "Noopept (omberacetam): What the evidence says", "kind": "compound", "focus_area": "Brain, mood & sleep", "focus_area_key": "neuro", "evidence_tier": "Very limited", "card_verdict": "Very limited (small Russian studies) · Healthy people: No data.", "card_note": "Not a peptide drug in the US, see page", "regulatory_status": "Not approved in the US · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · WADA: not named", "pmids": "12596521;19234797;19240853;22500312;34484905", "nct_ids": "", "search_aliases": "", "last_checked": "2026-10-26", "url": "https://openpeptideproject.org/library/noopept/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "octreotide", "title": "Octreotide", "full_title": "Octreotide: What the evidence says", "kind": "compound", "focus_area": "Hormones & fertility", "focus_area_key": "endocrine", "evidence_tier": "Strong", "card_verdict": "Strong (acromegaly, neuroendocrine tumors) · Gray-market: No human data.", "card_note": "Gallstone and heart-rate warnings, see page.", "regulatory_status": "FDA-approved: Sandostatin NDA 019667 (1988), Sandostatin LAR NDA 021008, Mycapssa NDA 208232, Bynfezia NDA 213224, generics · WADA: not named on the 2026 List", "pmids": "1416572;19704057;32882036", "nct_ids": "NCT03252353", "search_aliases": "sandostatin sandostatin lar mycapssa bynfezia somatostatin", "last_checked": "2026-10-25", "url": "https://openpeptideproject.org/library/octreotide/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "oligopeptide-1", "title": "sh-Oligopeptide-1 (recombinant human EGF, rhEGF)", "full_title": "sh-Oligopeptide-1 (recombinant human EGF, rhEGF): What the evidence says", "kind": "compound", "focus_area": "Skin, hair & aging", "focus_area_key": "skin", "evidence_tier": "Very limited", "card_verdict": "Very limited for cosmetic use; Moderate for diabetic foot ulcers (drug-grade rhEGF, not approved in the US).", "card_note": "Recombinant human EGF used in cosmetics", "regulatory_status": "Cosmetic ingredient; no FDA-approved EGF drug found · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · growth factors prohibited under WADA S2.3 (EGF not named)", "pmids": "20051095;32343054;37867626;42152512", "nct_ids": "", "search_aliases": "epidermal growth factor rhegf sh-oligopeptide-1 egf heberprot-p nepidermin wound healing diabetic foot ulcer", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/oligopeptide-1/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "orforglipron", "title": "Orforglipron", "full_title": "Orforglipron: What the evidence says", "kind": "compound", "focus_area": "Metabolic & weight", "focus_area_key": "metabolic", "evidence_tier": "Strong", "card_verdict": "Strong (weight; FDA-approved as Foundayo) · Type 2 diabetes: Moderate.", "card_note": "Varies by use, see page", "regulatory_status": "FDA-approved (Foundayo, NDA 220934, April 1, 2026) for chronic weight management only · Not FDA-approved for type 2 diabetes · EU, Japan, Canada: submitted per a review article [UNVERIFIED: not checked against EMA, PMDA or Health Canada] · China: [UNVERIFIED] not checked against NMPA · WADA: not named", "pmids": "37351564;37369232;40544435;40960239;41275875;41765029;42120723;42251769;42259339;42338042;42479349;42815506", "nct_ids": "NCT05048719;NCT05869903;NCT05872620;NCT06045221;NCT06584916;NCT07241390", "search_aliases": "ly3502970 oral non-peptide glp-1 agonist", "last_checked": "2026-10-25", "url": "https://openpeptideproject.org/library/orforglipron/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "ovagen", "title": "Ovagen", "full_title": "Ovagen: What the evidence says", "kind": "compound", "focus_area": "Longevity & bioregulators", "focus_area_key": "longevity", "evidence_tier": "No human data", "card_verdict": "No human data · No published studies of the marketed use (liver).", "card_note": "No published study tests the liver or digestive use it is sold for.", "regulatory_status": "Not FDA-approved (no Drugs@FDA entry found) · Russia: registration status [UNVERIFIED] · WADA: not named on the 2026 List ; S0 status [UNVERIFIED]", "pmids": "26515176;27909961;28744634", "nct_ids": "", "search_aliases": "edl glu-asp-leu liver gi bioregulator khavinson", "last_checked": "2026-10-25", "url": "https://openpeptideproject.org/library/ovagen/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "oxytocin", "title": "Oxytocin", "full_title": "Oxytocin: What the evidence says", "kind": "compound", "focus_area": "Brain, mood & sleep", "focus_area_key": "neuro", "evidence_tier": "Strong", "card_verdict": "Strong (labor induction & postpartum bleeding, hospital IV/IM use) · Weight loss & autism: Tested, not shown · Trust & mood: Very limited (mixed results) · Anti-aging: No human data.", "card_note": "Mixed use: the Strong rating covers only supervised hospital use in childbirth, not gray-market sprays. See page.", "regulatory_status": "FDA-approved as an injection only (Pitocin NDA 018261 and generics); nasal spray (Syntocinon) discontinued · 503B: Category 1 · WADA 2026: not named", "pmids": "8596357;15931222;19821304;25865294;29955161;32514040;34644471;38815173;40237648;41880977;42134427;42561025", "nct_ids": "", "search_aliases": "", "last_checked": "2026-10-26", "url": "https://openpeptideproject.org/library/oxytocin/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "p21", "title": "P21 (P021)", "full_title": "P21 (P021): What the evidence says", "kind": "compound", "focus_area": "Brain, mood & sleep", "focus_area_key": "neuro", "evidence_tier": "No human data", "card_verdict": "No human data (cognitive claims rest on Alzheimer's-model mouse studies from the developing lab).", "card_note": "", "regulatory_status": "Not FDA-approved (no Drugs@FDA record) · Not approved anywhere in the world · WADA 2026: S0 (unapproved substances) applies", "pmids": "25046994;34057082", "nct_ids": "", "search_aliases": "", "last_checked": "2026-10-25", "url": "https://openpeptideproject.org/library/p21/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "palmitoyl-tripeptide-38", "title": "Palmitoyl tripeptide-38 (Matrixyl synthe'6)", "full_title": "Palmitoyl tripeptide-38 (Matrixyl synthe'6): What the evidence says", "kind": "compound", "focus_area": "Skin, hair & aging", "focus_area_key": "skin", "evidence_tier": "Very limited", "card_verdict": "Very limited (one open-label, multi-ingredient study).", "card_note": "Cosmetic lipopeptide sold for wrinkles", "regulatory_status": "Cosmetic ingredient; not FDA-approved · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · not named by WADA", "pmids": "33103342", "nct_ids": "", "search_aliases": "matrixyl synthe'6 matrixyl synthe 6 pal-lys-mo2-lys-oh pal-kmo2k", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/palmitoyl-tripeptide-38/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "palopegteriparatide", "title": "Palopegteriparatide (Yorvipath, TransCon PTH)", "full_title": "Palopegteriparatide (Yorvipath, TransCon PTH): What the evidence says", "kind": "compound", "focus_area": "Hormones & fertility", "focus_area_key": "endocrine", "evidence_tier": "Strong", "card_verdict": "Strong (FDA-approved for adult hypoparathyroidism).", "card_note": "FDA-approved long-acting PTH replacement", "regulatory_status": "FDA-approved · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · not named by WADA", "pmids": "36271471;39376010", "nct_ids": "NCT04701203", "search_aliases": "yorvipath transcon pth acp-014 pth 1-34 prodrug hypoparathyroidism", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/palopegteriparatide/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "pancragen", "title": "Pancragen", "full_title": "Pancragen: What the evidence says", "kind": "compound", "focus_area": "Longevity & bioregulators", "focus_area_key": "longevity", "evidence_tier": "Very limited", "card_verdict": "Very limited (type 2 diabetes, one small Russian study).", "card_note": "Developer-led Russian study only, see page", "regulatory_status": "Not FDA-approved (no Drugs@FDA record) · Russia: registration status [UNVERIFIED] · WADA 2026: not named; S0 (unapproved substances) likely applies", "pmids": "22448364;23486591;25946840;28509500", "nct_ids": "", "search_aliases": "kedw lys-glu-asp-trp pancreas bioregulator khavinson", "last_checked": "2026-10-25", "url": "https://openpeptideproject.org/library/pancragen/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "parathyroid-hormone", "title": "Parathyroid hormone (PTH 1-84, Natpara)", "full_title": "Parathyroid hormone (PTH 1-84, Natpara): What the evidence says", "kind": "compound", "focus_area": "Hormones & fertility", "focus_area_key": "endocrine", "evidence_tier": "Moderate", "card_verdict": "Moderate (one phase 3 RCT; Natpara discontinued in the US).", "card_note": "Full-length PTH; Natpara discontinued", "regulatory_status": "FDA-licensed (BLA125511) but discontinued by the maker · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · not named by WADA", "pmids": "24622413;38741607", "nct_ids": "NCT00732615", "search_aliases": "natpara rhpth 1-84 rhpth(1-84) npsp558 full-length parathyroid hormone hypoparathyroidism", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/parathyroid-hormone/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "pasireotide", "title": "Pasireotide (Signifor / Signifor LAR)", "full_title": "Pasireotide (Signifor / Signifor LAR): What the evidence says", "kind": "compound", "focus_area": "Hormones & fertility", "focus_area_key": "endocrine", "evidence_tier": "Strong", "card_verdict": "Strong (FDA-approved for Cushing's disease and acromegaly; high hyperglycemia risk).", "card_note": "Prescription specialty drug", "regulatory_status": "FDA-approved · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · not named by WADA", "pmids": "22397653;24423324;25260838", "nct_ids": "", "search_aliases": "signifor signifor lar som230 cushing acromegaly", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/pasireotide/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "pe-22-28", "title": "PE-22-28 (mini-spadin)", "full_title": "PE-22-28 (mini-spadin): What the evidence says", "kind": "compound", "focus_area": "Brain, mood & sleep", "focus_area_key": "neuro", "evidence_tier": "No human data", "card_verdict": "No human data (antidepressant & stroke claims rest on mouse studies only).", "card_note": "Mouse data only, see page", "regulatory_status": "Never approved · Not on FDA 503A or 503B bulk lists · WADA 2026: not named; likely S0 ⚠️", "pmids": "20405001;21807005;25080852;28955242;30291907;31325429", "nct_ids": "", "search_aliases": "", "last_checked": "2026-10-26", "url": "https://openpeptideproject.org/library/pe-22-28/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "pegcetacoplan", "title": "Pegcetacoplan (Empaveli, Syfovre, APL-2)", "full_title": "Pegcetacoplan (Empaveli, Syfovre, APL-2): What the evidence says", "kind": "compound", "focus_area": "Immune & antimicrobial", "focus_area_key": "immune", "evidence_tier": "Strong", "card_verdict": "Strong (FDA-approved for PNH and geographic atrophy).", "card_note": "FDA-approved complement C3 inhibitor peptide", "regulatory_status": "FDA-approved · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · not named by WADA", "pmids": "33730455", "nct_ids": "", "search_aliases": "empaveli syfovre apl-2 compstatin c3 inhibitor pnh geographic atrophy", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/pegcetacoplan/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "pegozafermin", "title": "Pegozafermin", "full_title": "Pegozafermin: What the evidence says", "kind": "compound", "focus_area": "Metabolic & weight", "focus_area_key": "metabolic", "evidence_tier": "Moderate", "card_verdict": "Moderate (phase 2b MASH fibrosis & triglyceride RCTs; investigational).", "card_note": "Investigational; phase 3 under way", "regulatory_status": "Investigational, not FDA-approved · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · WADA S2.3 covers FGFs by class ⚠️ [UNVERIFIED] whether this analogue is captured", "pmids": "36521501;37355760;37356033", "nct_ids": "NCT04541186;NCT04929483;NCT05852431;NCT06318169;NCT06419374", "search_aliases": "bio89-100 glycopegylated fgf21 mash severe hypertriglyceridemia", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/pegozafermin/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "pegvisomant", "title": "Pegvisomant (Somavert)", "full_title": "Pegvisomant (Somavert): What the evidence says", "kind": "compound", "focus_area": "Hormones & fertility", "focus_area_key": "endocrine", "evidence_tier": "Strong", "card_verdict": "Strong (FDA-approved for acromegaly).", "card_note": "Prescription drug for acromegaly", "regulatory_status": "FDA-approved, BLA 021106 · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · not named on WADA's 2026 list", "pmids": "10770982;11734231;22362824", "nct_ids": "", "search_aliases": "somavert b2036-peg acromegaly gh receptor antagonist", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/pegvisomant/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "pemvidutide", "title": "Pemvidutide", "full_title": "Pemvidutide: What the evidence says", "kind": "compound", "focus_area": "Metabolic & weight", "focus_area_key": "metabolic", "evidence_tier": "Limited", "card_verdict": "Limited (MASH) · Weight: Very limited.", "card_note": "Varies by use, see page", "regulatory_status": "Not FDA-approved (no Drugs@FDA record) · FDA Breakthrough Therapy (MASH) and Fast Track (MASH, alcohol use disorder) per the company [UNVERIFIED: not confirmed on an FDA page] · EU, Japan, China: [UNVERIFIED] not checked against EMA, PMDA or NMPA · WADA: not named; S0 (unapproved substances) likely applies", "pmids": "39002641;41113119;41237796;41352959;41879841", "nct_ids": "NCT05006885;NCT05292911;NCT05989711;NCT06987513;NCT07009860;NCT07795164", "search_aliases": "alt-801 glp-1 glucagon dual agonist mash", "last_checked": "2026-10-25", "url": "https://openpeptideproject.org/library/pemvidutide/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "petrelintide", "title": "Petrelintide (ZP8396)", "full_title": "Petrelintide (ZP8396): What the evidence says", "kind": "compound", "focus_area": "Metabolic & weight", "focus_area_key": "metabolic", "evidence_tier": "Moderate", "card_verdict": "Moderate (phase 2, investigational weight loss).", "card_note": "Varies by use, see page", "regulatory_status": "Investigational · not on the 503A/503B lists or FDA's safety-risk page · not named on WADA's 2026 list", "pmids": "41217931;42017294;42810355", "nct_ids": "NCT06662539;NCT06926842;NCT07589686;NCT07843472;NCT07843485;NCT07843498", "search_aliases": "zp8396 amylin analog", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/petrelintide/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "phoenixin", "title": "Phoenixin (PNX-14, PNX-20)", "full_title": "Phoenixin (PNX-14, PNX-20): What the evidence says", "kind": "compound", "focus_area": "Hormones & fertility", "focus_area_key": "endocrine", "evidence_tier": "No human data", "card_verdict": "No human data (blood-level studies only; never tested as a treatment in people).", "card_note": "Natural brain peptide; never given to people as a treatment", "regulatory_status": "Not approved anywhere · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · not named on WADA's 2026 list; as a drug not approved anywhere for human use it falls under S0 (non-approved substances)", "pmids": "22963497;27440717;27989611;28176660;28624500", "nct_ids": "", "search_aliases": "pnx-14 pnx-20 pnx14 pnx20 smim20 gpr173 reproductive neuropeptide lh gnrh", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/phoenixin/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "pinealon", "title": "Pinealon", "full_title": "Pinealon: What the evidence says", "kind": "compound", "focus_area": "Longevity & bioregulators", "focus_area_key": "longevity", "evidence_tier": "Very limited", "card_verdict": "Very limited (oral capsules, Russian developer-network cohorts) · Injected vials, Alzheimer's, stroke: No human data.", "card_note": "Mixed use: the only human data are oral capsules; the injected vials sold online have never been tested in people. See page.", "regulatory_status": "Not an approved medicine in the US, EU or UK · not on FDA 503A/503B lists · Russia: sold as a dietary supplement ⚠️ [UNVERIFIED] · WADA 2026: not named; S0 likely applies (our reading)", "pmids": "21978084;22567179;22708445;23734521;26390612;28539017;28853087;33396470;39518916", "nct_ids": "", "search_aliases": "edr glu-asp-arg khavinson", "last_checked": "2026-10-26", "url": "https://openpeptideproject.org/library/pinealon/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "plecanatide", "title": "Plecanatide (Trulance)", "full_title": "Plecanatide (Trulance): What the evidence says", "kind": "compound", "focus_area": "Heart, blood & gut", "focus_area_key": "cardio", "evidence_tier": "Strong", "card_verdict": "Strong (FDA-approved for adult chronic constipation and IBS-C).", "card_note": "Varies by use, see page", "regulatory_status": "FDA-approved (NDA 208745) · not on the 503A/503B lists or FDA's safety-risk page · not named on WADA's 2026 list", "pmids": "28169285;29147135;29545635;30277094", "nct_ids": "NCT01982240;NCT02122471;NCT02706483", "search_aliases": "trulance uroguanylin guanylate cyclase constipation ibs-c", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/plecanatide/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "pluvicto-lu-177-vipivotide-tetraxetan", "title": "Lutetium Lu 177 vipivotide tetraxetan (Pluvicto, 177Lu-PSMA-617)", "full_title": "Lutetium Lu 177 vipivotide tetraxetan (Pluvicto, 177Lu-PSMA-617): What the evidence says", "kind": "compound", "focus_area": "Hormones & fertility", "focus_area_key": "endocrine", "evidence_tier": "Strong", "card_verdict": "Strong (FDA-approved radioligand therapy for PSMA-positive metastatic prostate cancer).", "card_note": "FDA-approved PSMA-targeted radioligand therapy", "regulatory_status": "FDA-approved · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · not named by WADA", "pmids": "34161051;39293462;42561994", "nct_ids": "NCT03511664;NCT04689828", "search_aliases": "pluvicto lu-177-psma-617 177lu-psma-617 vipivotide tetraxetan psma-617 radioligand prostate cancer vision psmafore", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/pluvicto-lu-177-vipivotide-tetraxetan/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "pn-943", "title": "PN-943", "full_title": "PN-943: What the evidence says", "kind": "compound", "focus_area": "Heart, blood & gut", "focus_area_key": "cardio", "evidence_tier": "Very limited", "card_verdict": "Very limited (one phase 2 RCT, reported only by the company; development stopped).", "card_note": "Discontinued oral gut-acting α4β7 integrin-blocking peptide", "regulatory_status": "Never approved; development stopped · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · not named on WADA's 2026 list; as a drug not approved anywhere for human use it falls under S0 (non-approved substances)", "pmids": "33942566", "nct_ids": "NCT04504383", "search_aliases": "pn943 oral alpha4beta7 integrin antagonist peptide ulcerative colitis ibd ideal trial", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/pn-943/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "pnc-27", "title": "PNC-27", "full_title": "PNC-27: What the evidence says", "kind": "compound", "focus_area": "Immune & antimicrobial", "focus_area_key": "immune", "evidence_tier": "No human data", "card_verdict": "No human data · Lab and mouse only.", "card_note": "No human trials, see page", "regulatory_status": "Never approved · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · WADA: not named", "pmids": "16688716;20080680;20182728;26663795", "nct_ids": "", "search_aliases": "", "last_checked": "2026-10-26", "url": "https://openpeptideproject.org/library/pnc-27/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "pramlintide", "title": "Pramlintide", "full_title": "Pramlintide: What the evidence says", "kind": "compound", "focus_area": "Metabolic & weight", "focus_area_key": "metabolic", "evidence_tier": "Strong", "card_verdict": "Strong (add-on to mealtime insulin) · Gray-market vials: No human data · Boxed warning: severe low blood sugar.", "card_note": "Severe hypoglycemia risk with insulin, see page.", "regulatory_status": "FDA-approved: Symlin NDA 021332 (Mar 16, 2005); Drugs@FDA lists Symlin products as Discontinued · boxed warning · WADA: not named on the 2026 List", "pmids": "12610038;15498087", "nct_ids": "", "search_aliases": "symlin amylin analog diabetes", "last_checked": "2026-10-25", "url": "https://openpeptideproject.org/library/pramlintide/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "prostamax", "title": "Prostamax", "full_title": "Prostamax: What the evidence says", "kind": "compound", "focus_area": "Longevity & bioregulators", "focus_area_key": "longevity", "evidence_tier": "No human data", "card_verdict": "No human data (prostate claims rest on rat tissue and white-blood-cell dish studies only).", "card_note": "Animal/lab data only (developer-led), see page", "regulatory_status": "Not FDA-approved (no Drugs@FDA record) · Russia: registration status [UNVERIFIED] · WADA 2026: not named; S0 (unapproved substances) likely applies", "pmids": "15085253;17152728;23221144", "nct_ids": "", "search_aliases": "kedp lys-glu-asp-pro prostate bioregulator khavinson", "last_checked": "2026-10-25", "url": "https://openpeptideproject.org/library/prostamax/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "pt-141", "title": "PT-141 (bremelanotide)", "full_title": "PT-141 (bremelanotide): What the evidence says", "kind": "compound", "focus_area": "Brain, mood & sleep", "focus_area_key": "neuro", "evidence_tier": "Moderate", "card_verdict": "Moderate (premenopausal HSDD, FDA-approved as Vyleesi; small effects) · Men / healthy people: Very limited or no human data.", "card_note": "Mixed use: approved for one condition in premenopausal women; the label says it is not for men or for enhancing performance. See page.", "regulatory_status": "US: FDA-approved (Vyleesi, NDA 210557, June 21, 2019), premenopausal HSDD only; label says not for men or to enhance performance · EU: not authorised (not in EMA's medicines list) · WADA 2026: not named; our reading below", "pmids": "14963471;14999221;15292097;15833522;18179455;18206919;31599840;31599847;35147466;36626345;36809187", "nct_ids": "NCT02333071;NCT02338960", "search_aliases": "bremelanotide vyleesi mc4r female hypoactive sexual desire erectile", "last_checked": "2026-10-26", "url": "https://openpeptideproject.org/library/pt-141/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "rad-140", "title": "RAD-140 (testolone)", "full_title": "RAD-140 (testolone): What the evidence says", "kind": "compound", "focus_area": "Muscle, bone & recovery", "focus_area_key": "muscle", "evidence_tier": "Very limited", "card_verdict": "Very limited (one small phase 1 in breast cancer; liver-injury case reports; not a peptide).", "card_note": "Investigational oral SARM; small molecule", "regulatory_status": "Not FDA-approved · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · named on WADA S1.2", "pmids": "22459616;28974548;29183075;33062783;34565686;36479151;36561105;36978171;37218811;38059982;38444893;39755947;40761329;42919612", "nct_ids": "NCT03088527", "search_aliases": "testolone rad140 vosilasarm non-steroidal sarm selective androgen receptor modulator", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/rad-140/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "relamorelin", "title": "Relamorelin (RM-131)", "full_title": "Relamorelin (RM-131): What the evidence says", "kind": "compound", "focus_area": "Heart, blood & gut", "focus_area_key": "cardio", "evidence_tier": "Limited", "card_verdict": "Limited (positive phase 2 RCTs, but phase 3 results showed no clear benefit; development stopped).", "card_note": "Discontinued ghrelin-mimicking injection for gastroparesis", "regulatory_status": "Never approved; development stopped · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · not named by WADA, but as a ghrelin-receptor agonist it falls in the GHS-mimetic class under S2.2.4", "pmids": "26467700;27055601;28237854;28760384;32301137", "nct_ids": "NCT02357420;NCT03285308;NCT03383146;NCT03420781;NCT03426345", "search_aliases": "rm-131 rm131 bim-28163 ghrelin receptor agonist pentapeptide diabetic gastroparesis", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/relamorelin/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "retatrutide", "title": "Retatrutide", "full_title": "Retatrutide: What the evidence says", "kind": "compound", "focus_area": "Metabolic & weight", "focus_area_key": "metabolic", "evidence_tier": "Moderate", "card_verdict": "Moderate (weight loss, type 2 diabetes, knee osteoarthritis & liver fat in phase 2/3 trials; not FDA-approved).", "card_note": "", "regulatory_status": "Not FDA-approved (Lilly plans Q1 2027 FDA filing) · cannot be used in compounding · FDA has warned sellers of \"research purposes\" retatrutide · WADA 2026: S0 non-approved substances class, prohibited at all times", "pmids": "37366315;37385280;39509151;42250575;42810372;42814954;42843917;42853576", "nct_ids": "", "search_aliases": "ly3437943 triple g glp-1 gip glucagon weight loss", "last_checked": "2026-10-24", "url": "https://openpeptideproject.org/library/retatrutide/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "rigin", "title": "Rigin (palmitoyl tetrapeptide-7, Pal-GQPR)", "full_title": "Rigin (palmitoyl tetrapeptide-7, Pal-GQPR): What the evidence says", "kind": "compound", "focus_area": "Skin, hair & aging", "focus_area_key": "skin", "evidence_tier": "Very limited", "card_verdict": "Very limited (multi-ingredient cosmetic cream study only; never inject).", "card_note": "Topical skincare peptide; not a drug", "regulatory_status": "Cosmetic ingredient, not a drug · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · not named by WADA", "pmids": "18045359;38932444", "nct_ids": "", "search_aliases": "palmitoyl tetrapeptide-7 pal-gqpr", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/rigin/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "romidepsin", "title": "Romidepsin (Istodax, FK228)", "full_title": "Romidepsin (Istodax, FK228): What the evidence says", "kind": "compound", "focus_area": "Immune & antimicrobial", "focus_area_key": "immune", "evidence_tier": "Moderate", "card_verdict": "Moderate (FDA-approved for CTCL from single-arm trials; PTCL indication withdrawn).", "card_note": "FDA-approved depsipeptide cancer drug", "regulatory_status": "FDA-approved · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · not named by WADA", "pmids": "38364196", "nct_ids": "", "search_aliases": "istodax fk228 fr901228 depsipeptide hdac inhibitor lymphoma ctcl", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/romidepsin/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "romiplostim", "title": "Romiplostim (Nplate, AMG 531)", "full_title": "Romiplostim (Nplate, AMG 531): What the evidence says", "kind": "compound", "focus_area": "Heart, blood & gut", "focus_area_key": "cardio", "evidence_tier": "Strong", "card_verdict": "Strong (FDA-approved for immune thrombocytopenia).", "card_note": "FDA-approved platelet-raising Fc-peptide fusion", "regulatory_status": "FDA-approved · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · not named by WADA", "pmids": "18242413;18981291", "nct_ids": "", "search_aliases": "nplate amg 531 peptibody tpo thrombopoietin itp platelets", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/romiplostim/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "rubiscolin-6", "title": "Rubiscolin-6 (YPLDLF)", "full_title": "Rubiscolin-6 (YPLDLF): What the evidence says", "kind": "compound", "focus_area": "Brain, mood & sleep", "focus_area_key": "neuro", "evidence_tier": "No human data", "card_verdict": "No human data (spinach-derived opioid hexapeptide; mouse data only).", "card_note": "Research peptide from spinach Rubisco; not a drug", "regulatory_status": "Not FDA-approved · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · not named by WADA", "pmids": "11741591;12668220;17766012;37373107", "nct_ids": "", "search_aliases": "", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/rubiscolin-6/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "rusfertide", "title": "Rusfertide (Mimrylo, PTG-300)", "full_title": "Rusfertide (Mimrylo, PTG-300): What the evidence says", "kind": "compound", "focus_area": "Heart, blood & gut", "focus_area_key": "cardio", "evidence_tier": "Strong", "card_verdict": "Strong (FDA-approved hepcidin mimetic for polycythemia vera).", "card_note": "FDA-approved hepcidin-mimetic peptide", "regulatory_status": "FDA-approved · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · not named by WADA", "pmids": "38381675;42868322", "nct_ids": "NCT04057040;NCT05210790", "search_aliases": "mimrylo ptg-300 ptg300 hepcidin mimetic polycythemia vera hematocrit phlebotomy verify revive", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/rusfertide/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "secretin", "title": "Secretin (ChiRhoStim)", "full_title": "Secretin (ChiRhoStim): What the evidence says", "kind": "compound", "focus_area": "Heart, blood & gut", "focus_area_key": "cardio", "evidence_tier": "Strong", "card_verdict": "Strong (FDA-approved pancreatic/gastrinoma diagnostic; proven ineffective for autism in 15+ RCTs).", "card_note": "FDA-approved diagnostic hormone; not a treatment", "regulatory_status": "FDA-approved diagnostic ; SecreFlo discontinued · 503A and 503B Category 3 (human secretin) · not named by WADA", "pmids": "10588965;15590241", "nct_ids": "", "search_aliases": "chirhostim secreflo pancreatic diagnostic", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/secretin/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "selank", "title": "Selank", "full_title": "Selank: What the evidence says", "kind": "compound", "focus_area": "Brain, mood & sleep", "focus_area_key": "neuro", "evidence_tier": "Limited", "card_verdict": "Limited (generalized anxiety, small Russian trials) · Brain fMRI (single dose): Very limited · Nootropic/wellness use: No human data.", "card_note": "Varies by use, see page", "regulatory_status": "Not FDA-approved (no Drugs@FDA record) · Not on 503A Bulks List; FDA flagged immunogenicity/impurity risks (`FDA-2023-N-3392-0011`) · Registered in Russia as 0.15% nasal drops (`ЛСР-003338/09`, Vidal.ru mirror; direct GRLS `[UNVERIFIED]`) · WADA 2026: not named; S0 status of Russian-only drugs unruled", "pmids": "18454096;25176261;31667971;32342318", "nct_ids": "", "search_aliases": "", "last_checked": "2026-10-25", "url": "https://openpeptideproject.org/library/selank/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "semaglutide", "title": "Semaglutide", "full_title": "Semaglutide: What the evidence says", "kind": "compound", "focus_area": "Metabolic & weight", "focus_area_key": "metabolic", "evidence_tier": "Strong", "card_verdict": "Strong (weight loss, type 2 diabetes, MASH, heart & kidney protection; FDA-approved as Ozempic, Wegovy & Rybelsus).", "card_note": "", "regulatory_status": "FDA-approved (Ozempic, Rybelsus, Wegovy) · not named on WADA's 2026 list · FDA shortage over; copies of approved products generally can no longer be compounded", "pmids": "27633186;31185157;33567185;37952131;39509151", "nct_ids": "", "search_aliases": "ozempic wegovy rybelsus glp-1 glp1 weight loss diabetes", "last_checked": "2026-10-15", "url": "https://openpeptideproject.org/library/semaglutide/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "semax", "title": "Semax", "full_title": "Semax: What the evidence says", "kind": "compound", "focus_area": "Brain, mood & sleep", "focus_area_key": "neuro", "evidence_tier": "Limited", "card_verdict": "Limited (acute ischemic stroke, small Russian studies) · Brain fMRI (single dose): Very limited · Nootropic/wellness use: No human data.", "card_note": "Varies by use, see page", "regulatory_status": "Not FDA-approved (no Drugs@FDA record) · Not on 503A Bulks List; reviewed at FDA's July 23–24, 2026 PCAC meeting (`FDA media 193348`) · Registered in Russia as 0.1% (`Р N000812/01`) and 1% (`ЛСР-000167/08`) nasal drops (Vidal.ru mirror; direct GRLS `[UNVERIFIED]`) · WADA 2026: not named; S0 status of Russian-only drugs unruled", "pmids": "11517472;29798983;30225715;31667971;32342318", "nct_ids": "", "search_aliases": "", "last_checked": "2026-10-25", "url": "https://openpeptideproject.org/library/semax/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "sermorelin", "title": "Sermorelin", "full_title": "Sermorelin: What the evidence says", "kind": "compound", "focus_area": "Hormones & fertility", "focus_area_key": "endocrine", "evidence_tier": "Moderate", "card_verdict": "Moderate (pituitary diagnostic test, former FDA approval) · Childhood GH deficiency: Limited · Adult anti-aging, body composition, energy: Very limited.", "card_note": "Mixed use: the higher ratings apply to a discontinued medical product in children and testing, not to clinic \"anti-aging\" use. See page.", "regulatory_status": "No current FDA approval (Geref NDAs 019863 and 020443 discontinued; approvals withdrawn 2009, not for safety or effectiveness) · 503B: Category 1 · WADA 2026: prohibited at all times (S2.2.4, named)", "pmids": "8772599;9141536;18031173;19509104;28830317", "nct_ids": "", "search_aliases": "", "last_checked": "2026-10-26", "url": "https://openpeptideproject.org/library/sermorelin/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "setmelanotide", "title": "Setmelanotide", "full_title": "Setmelanotide: What the evidence says", "kind": "compound", "focus_area": "Metabolic & weight", "focus_area_key": "metabolic", "evidence_tier": "Moderate", "card_verdict": "Moderate (approved use: rare genetic obesity) · General or gray-market weight loss: No human data.", "card_note": "Gray-market vials are not the approved product, see page.", "regulatory_status": "FDA-approved (Imcivree, NDA 213793; label on DailyMed) · other regulators [UNVERIFIED] · WADA: not named on the 2026 List", "pmids": "33137293;36356613", "nct_ids": "", "search_aliases": "imcivree rm-493 mc4r agonist genetic obesity bardet-biedl", "last_checked": "2026-10-25", "url": "https://openpeptideproject.org/library/setmelanotide/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "sigumir", "title": "Sigumir (cartilage peptide complex)", "full_title": "Sigumir (cartilage peptide complex): What the evidence says", "kind": "compound", "focus_area": "Longevity & bioregulators", "focus_area_key": "longevity", "evidence_tier": "No human data", "card_verdict": "No human data (no indexed peer-reviewed clinical trial found).", "card_note": "Russian oral tissue-extract supplement; no indexed trials", "regulatory_status": "Not FDA-approved · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · not named by WADA", "pmids": "37782637", "nct_ids": "", "search_aliases": "a-4 cartilage cytomax khavinson", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/sigumir/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "sincalide", "title": "Sincalide (Kinevac, CCK-8)", "full_title": "Sincalide (Kinevac, CCK-8): What the evidence says", "kind": "compound", "focus_area": "Heart, blood & gut", "focus_area_key": "cardio", "evidence_tier": "Moderate", "card_verdict": "Moderate (FDA-approved diagnostic agent; usefulness of the gallbladder test is debated).", "card_note": "FDA-approved diagnostic octapeptide of cholecystokinin", "regulatory_status": "FDA-approved diagnostic · not on FDA's 503A list; on the 503B list in Category 1 (under evaluation) · not on FDA's safety-risk page · not named by WADA", "pmids": "20080900;22293163", "nct_ids": "", "search_aliases": "kinevac cck-8 cholecystokinin octapeptide gallbladder ejection fraction hida scan pancreatic diagnostic", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/sincalide/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "slu-pp-332", "title": "SLU-PP-332", "full_title": "SLU-PP-332: What the evidence says", "kind": "compound", "focus_area": "Metabolic & weight", "focus_area_key": "metabolic", "evidence_tier": "No human data", "card_verdict": "No human data (exercise-mimic & fat-loss claims rest on mouse studies only).", "card_note": "Not a peptide; mouse data only, see page", "regulatory_status": "Never approved · Not on FDA 503A or 503B bulk lists · WADA 2026: not named; anti-doping labs treat it as a prohibited-class candidate ⚠️", "pmids": "36988910;37717940;37739806;37961903;40692696;41421047;41588687;41688415", "nct_ids": "", "search_aliases": "err agonist exercise mimetic", "last_checked": "2026-10-26", "url": "https://openpeptideproject.org/library/slu-pp-332/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "snap-8", "title": "SNAP-8 (acetyl octapeptide-3)", "full_title": "SNAP-8 (acetyl octapeptide-3): What the evidence says", "kind": "compound", "focus_area": "Skin, hair & aging", "focus_area_key": "skin", "evidence_tier": "Very limited", "card_verdict": "Very limited (wrinkles, only in multi-ingredient skin products) · Injected: No human data.", "card_note": "Mixed use: a cosmetic cream ingredient; \"research\" powders for injection have no human data. See page.", "regulatory_status": "Cosmetic ingredient, not a drug · US: not FDA-approved (cosmetics are not pre-approved) · WADA 2026: not named", "pmids": "18498523;31134751;33195061;35426243;37861918;39082657;39858482;40292641;40673537", "nct_ids": "", "search_aliases": "acetyl octapeptide-3 wrinkle octapeptide", "last_checked": "2026-10-26", "url": "https://openpeptideproject.org/library/snap-8/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "somapacitan", "title": "Somapacitan (Sogroya, somapacitan-beco)", "full_title": "Somapacitan (Sogroya, somapacitan-beco): What the evidence says", "kind": "compound", "focus_area": "Hormones & fertility", "focus_area_key": "endocrine", "evidence_tier": "Strong", "card_verdict": "Strong (FDA-approved long-acting growth hormone).", "card_note": "FDA-approved long-acting growth hormone", "regulatory_status": "FDA-approved · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · prohibited at all times (WADA S2.2.3)", "pmids": "32022863;36062966", "nct_ids": "NCT02229851;NCT03811535", "search_aliases": "sogroya somapacitan-beco nnc0195-0092 once-weekly growth hormone hgh ghd", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/somapacitan/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "somatrogon", "title": "Somatrogon (Ngenla, somatrogon-ghla)", "full_title": "Somatrogon (Ngenla, somatrogon-ghla): What the evidence says", "kind": "compound", "focus_area": "Hormones & fertility", "focus_area_key": "endocrine", "evidence_tier": "Strong", "card_verdict": "Strong (FDA-approved weekly growth hormone for children with GH deficiency).", "card_note": "FDA-approved long-acting growth hormone for children", "regulatory_status": "FDA-approved · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · prohibited at all times (WADA S2.2.3)", "pmids": "35405011;41879875", "nct_ids": "NCT02968004", "search_aliases": "ngenla somatrogon-ghla mod-4023 pf-06836922 ctp-modified hgh once-weekly growth hormone ghd", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/somatrogon/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "spexin", "title": "Spexin (neuropeptide Q, NPQ)", "full_title": "Spexin (neuropeptide Q, NPQ): What the evidence says", "kind": "compound", "focus_area": "Metabolic & weight", "focus_area_key": "metabolic", "evidence_tier": "No human data", "card_verdict": "No human data (blood-level studies only; never tested as a treatment in people).", "card_note": "Natural 14-amino-acid peptide; never given to people as a treatment", "regulatory_status": "Not approved anywhere · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · not named on WADA's 2026 list; as a drug not approved anywhere for human use it falls under S0 (non-approved substances)", "pmids": "17284679;24550067;33520870;36914115;41597393;42039133", "nct_ids": "", "search_aliases": "npq neuropeptide q c12orf39 galr2 galr3 satiety metabolic neuropeptide", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/spexin/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "sr9009", "title": "SR9009 (Stenabolic)", "full_title": "SR9009 (Stenabolic): What the evidence says", "kind": "compound", "focus_area": "Metabolic & weight", "focus_area_key": "metabolic", "evidence_tier": "No human data", "card_verdict": "No human data.", "card_note": "Not a peptide; prohibited in sport", "regulatory_status": "Never approved; not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · Prohibited at all times, WADA S4.4.1", "pmids": "22460951;23852339;31127047", "nct_ids": "", "search_aliases": "stenabolic rev-erb agonist", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/sr9009/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "ss-31", "title": "SS-31 (elamipretide)", "full_title": "SS-31 (elamipretide): What the evidence says", "kind": "compound", "focus_area": "Longevity & bioregulators", "focus_area_key": "longevity", "evidence_tier": "Very limited", "card_verdict": "Very limited (Barth syndrome, FDA accelerated approval; other diseases: mixed results) · Energy, endurance, anti-aging in healthy people: No human data.", "card_note": "Mixed use: approved for one rare disease on a muscle-strength measure; never tested in healthy people. See page.", "regulatory_status": "US: FDA accelerated approval (Forzinity, NDA 215244), Barth syndrome only, Sept 19, 2025 · EU: not authorised (orphan designations only) · 503A/503B: not nominated · WADA 2026: not named; our reading is that it is not prohibited (not a WADA ruling)", "pmids": "32068002;33077895;37268435;37923251;38602181;39574155;39605874;39940712;41335372;42290373", "nct_ids": "NCT02693119;NCT02788747;NCT03098797;NCT03323749;NCT03891875", "search_aliases": "elamipretide forzinity mtp-131 bendavia barth syndrome mitochondria cardiolipin", "last_checked": "2026-10-26", "url": "https://openpeptideproject.org/library/ss-31/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "stamakort", "title": "Stamakort (stomach mucosa peptide complex)", "full_title": "Stamakort (stomach mucosa peptide complex): What the evidence says", "kind": "compound", "focus_area": "Longevity & bioregulators", "focus_area_key": "longevity", "evidence_tier": "No human data", "card_verdict": "No human data (no indexed peer-reviewed clinical trial found).", "card_note": "Russian oral tissue-extract supplement; no indexed trials", "regulatory_status": "Not FDA-approved · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · not named by WADA", "pmids": "22803148", "nct_ids": "", "search_aliases": "a-10 stomach cytomax khavinson", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/stamakort/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "suprefort", "title": "Suprefort (pancreas peptide complex)", "full_title": "Suprefort (pancreas peptide complex): What the evidence says", "kind": "compound", "focus_area": "Longevity & bioregulators", "focus_area_key": "longevity", "evidence_tier": "No human data", "card_verdict": "No human data (no indexed peer-reviewed clinical trial found).", "card_note": "Russian oral tissue-extract supplement; no indexed trials", "regulatory_status": "Not FDA-approved · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · not named by WADA", "pmids": "23486591", "nct_ids": "", "search_aliases": "a-1 pancreas cytomax khavinson", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/suprefort/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "survodutide", "title": "Survodutide", "full_title": "Survodutide: What the evidence says", "kind": "compound", "focus_area": "Metabolic & weight", "focus_area_key": "metabolic", "evidence_tier": "Moderate", "card_verdict": "Moderate (weight) · MASH and type 2 diabetes: Limited.", "card_note": "Varies by use, see page", "regulatory_status": "Not FDA-approved (no Drugs@FDA record) · FDA Fast Track and Breakthrough Therapy designations for MASH per the company [UNVERIFIED: not confirmed on an FDA page] · EU, Japan, China: [UNVERIFIED] not checked against EMA, PMDA or NMPA · WADA: not named; S0 (unapproved substances) likely applies", "pmids": "36356832;38095657;38330987;38847460;38857788;42252333;42253238;42820639", "nct_ids": "NCT04153929;NCT04667377;NCT04771273;NCT06066515;NCT06066528;NCT06077864;NCT06632444;NCT06632457;NCT07754461", "search_aliases": "bi 456906 bi-456906 glucagon glp-1 dual agonist mash obesity", "last_checked": "2026-10-25", "url": "https://openpeptideproject.org/library/survodutide/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "svetinorm", "title": "Svetinorm (liver peptide complex)", "full_title": "Svetinorm (liver peptide complex): What the evidence says", "kind": "compound", "focus_area": "Longevity & bioregulators", "focus_area_key": "longevity", "evidence_tier": "No human data", "card_verdict": "No human data (no indexed peer-reviewed clinical trial found).", "card_note": "Russian oral tissue-extract supplement; no indexed trials", "regulatory_status": "Not FDA-approved · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · not named by WADA", "pmids": "32362099", "nct_ids": "", "search_aliases": "a-7 liver cytomax khavinson", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/svetinorm/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "syn-ake", "title": "Syn-Ake (dipeptide diaminobutyroyl benzylamide diacetate)", "full_title": "Syn-Ake (dipeptide diaminobutyroyl benzylamide diacetate): What the evidence says", "kind": "compound", "focus_area": "Skin, hair & aging", "focus_area_key": "skin", "evidence_tier": "No human data", "card_verdict": "No human data (for Syn-Ake alone).", "card_note": "Varies by use, see page", "regulatory_status": "Cosmetic ingredient, not a drug · not on the 503A/503B lists or FDA's safety-risk page · not named on WADA's 2026 list", "pmids": "10087048;37349941;41668671;42927054", "nct_ids": "", "search_aliases": "dipeptide diaminobutyroyl benzylamide diacetate waglerin-1", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/syn-ake/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "syn-coll", "title": "Syn-Coll (palmitoyl tripeptide-5, Pal-KVK)", "full_title": "Syn-Coll (palmitoyl tripeptide-5, Pal-KVK): What the evidence says", "kind": "compound", "focus_area": "Skin, hair & aging", "focus_area_key": "skin", "evidence_tier": "No human data", "card_verdict": "No human data (supplier cosmetic claims only; no peer-reviewed trial; never inject).", "card_note": "Topical skincare peptide; not a drug", "regulatory_status": "Cosmetic ingredient, not a drug · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · not named by WADA", "pmids": "18045359", "nct_ids": "", "search_aliases": "palmitoyl tripeptide-5 pal-kvk tgf-beta", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/syn-coll/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "taldefgrobep-alfa", "title": "Taldefgrobep alfa (BHV-2000, BMS-986089, RG6206)", "full_title": "Taldefgrobep alfa (BHV-2000, BMS-986089, RG6206): What the evidence says", "kind": "compound", "focus_area": "Muscle, bone & recovery", "focus_area_key": "muscle", "evidence_tier": "Limited", "card_verdict": "Limited (failed in DMD; SMA phase 3 reportedly missed; obesity trial ongoing).", "card_note": "Investigational anti-myostatin protein", "regulatory_status": "Investigational · not FDA-approved · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · banned by WADA S4.3", "pmids": "38190001;39408601;41566720", "nct_ids": "NCT02515669;NCT05337553;NCT07281495", "search_aliases": "bhv-2000 bms-986089 rg6206 anti-myostatin adnectin sma obesity", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/taldefgrobep-alfa/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "taxorest", "title": "Taxorest (bronchial peptide complex)", "full_title": "Taxorest (bronchial peptide complex): What the evidence says", "kind": "compound", "focus_area": "Longevity & bioregulators", "focus_area_key": "longevity", "evidence_tier": "No human data", "card_verdict": "No human data (no indexed peer-reviewed clinical trial found).", "card_note": "Russian oral tissue-extract supplement; no indexed trials", "regulatory_status": "Not FDA-approved · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · not named by WADA", "pmids": "25015171", "nct_ids": "", "search_aliases": "a-19 bronchial cytomax khavinson", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/taxorest/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "tb-500", "title": "TB-500 and thymosin beta-4", "full_title": "TB-500 and thymosin beta-4: What the evidence says", "kind": "compound", "focus_area": "Muscle, bone & recovery", "focus_area_key": "muscle", "evidence_tier": "Limited", "card_verdict": "Limited (full Thymosin beta-4 protein, topical/eye drops) · TB-500 fragment or injected healing/recovery: No human data.", "card_note": "Varies by use, see page", "regulatory_status": "Not FDA-approved · WADA-banned (Tβ4 and derivatives, e.g. TB-500)", "pmids": "10469335;15565145;17495250;20536472;22856429;22962027;23050815;25826322;26056426;34346165;38382158", "nct_ids": "", "search_aliases": "thymosin beta-4 timbetasin rgn-259 rgn-352 lkktenq", "last_checked": "2026-10-15", "url": "https://openpeptideproject.org/library/tb-500/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "teduglutide", "title": "Teduglutide", "full_title": "Teduglutide: What the evidence says", "kind": "compound", "focus_area": "Heart, blood & gut", "focus_area_key": "cardio", "evidence_tier": "Moderate", "card_verdict": "Moderate (short bowel syndrome on IV nutrition) · \"Gut repair\" uses: No human data.", "card_note": "Tumor-growth warning; never tested for general gut health, see page.", "regulatory_status": "FDA-approved: Gattex NDA 203441 (Dec 21, 2012) · WADA: not named on the 2026 List", "pmids": "21317170;22982184", "nct_ids": "NCT00798967", "search_aliases": "gattex revestive glp-2 short bowel syndrome", "last_checked": "2026-10-25", "url": "https://openpeptideproject.org/library/teduglutide/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "teriparatide", "title": "Teriparatide", "full_title": "Teriparatide: What the evidence says", "kind": "compound", "focus_area": "Muscle, bone & recovery", "focus_area_key": "muscle", "evidence_tier": "Strong", "card_verdict": "Strong (osteoporosis fractures) · Fracture healing: mixed results · Gray-market: No human data.", "card_note": "Not approved for fracture healing; osteosarcoma precautions remain, see page.", "regulatory_status": "FDA-approved: Forteo NDA 021318 (Nov 26, 2002); Bonsity NDA 211939; generic ANDA 213641 (Amphastar, Dec 12, 2025) · no boxed warning on current label · WADA: not named on the 2026 List", "pmids": "11346808;19594305;32990990;36111201", "nct_ids": "", "search_aliases": "forteo pth 1-34 parathyroid hormone osteoporosis bone", "last_checked": "2026-10-25", "url": "https://openpeptideproject.org/library/teriparatide/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "tesamorelin", "title": "Tesamorelin", "full_title": "Tesamorelin: What the evidence says", "kind": "compound", "focus_area": "Metabolic & weight", "focus_area_key": "metabolic", "evidence_tier": "Strong", "card_verdict": "Strong (HIV belly fat, FDA-approved as Egrifta) · HIV fatty liver: Limited · General fat loss or anti-aging without HIV: No human data.", "card_note": "Varies by use, see page", "regulatory_status": "FDA-approved (HIV lipodystrophy only) · WADA-banned", "pmids": "20101189;20554713;31611038", "nct_ids": "", "search_aliases": "egrifta egrifta sv th9507 ghrh visceral fat", "last_checked": "2026-10-15", "url": "https://openpeptideproject.org/library/tesamorelin/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "tesofensine", "title": "Tesofensine", "full_title": "Tesofensine: What the evidence says", "kind": "compound", "focus_area": "Metabolic & weight", "focus_area_key": "metabolic", "evidence_tier": "Limited", "card_verdict": "Limited (weight loss, phase 2 trial under expression of concern).", "card_note": "", "regulatory_status": "Not FDA-approved (no Drugs@FDA record) · Mexico: reported approved for obesity [UNVERIFIED: not confirmed on COFEPRIS primary registry] · WADA 2026: prohibited in-competition (S6.b specified stimulant, named)", "pmids": "18950853;20520602;23561987;35294397;42320973", "nct_ids": "NCT00394667", "search_aliases": "", "last_checked": "2026-10-25", "url": "https://openpeptideproject.org/library/tesofensine/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "testagen", "title": "Testagen", "full_title": "Testagen: What the evidence says", "kind": "compound", "focus_area": "Longevity & bioregulators", "focus_area_key": "longevity", "evidence_tier": "No human data", "card_verdict": "No human data (testicular claims untested; only studied in pituitary-removed birds).", "card_note": "No study found tests the testicular use the product is sold for.", "regulatory_status": "Not FDA-approved (no Drugs@FDA record) · Russia: registration status [UNVERIFIED] · WADA 2026: not named; S0 (unapproved substances) likely applies", "pmids": "22268052;23658898", "nct_ids": "", "search_aliases": "kedg lys-glu-asp-gly testis bioregulator khavinson", "last_checked": "2026-10-25", "url": "https://openpeptideproject.org/library/testagen/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "testoluten", "title": "Testoluten (testis peptide complex)", "full_title": "Testoluten (testis peptide complex): What the evidence says", "kind": "compound", "focus_area": "Longevity & bioregulators", "focus_area_key": "longevity", "evidence_tier": "No human data", "card_verdict": "No human data (no indexed peer-reviewed clinical trial found).", "card_note": "Russian oral tissue-extract supplement; no indexed trials", "regulatory_status": "Not FDA-approved · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · not named by WADA", "pmids": "12374906", "nct_ids": "", "search_aliases": "a-13 testis cytomax khavinson", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/testoluten/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "thymalin", "title": "Thymalin", "full_title": "Thymalin: What the evidence says", "kind": "compound", "focus_area": "Immune & antimicrobial", "focus_area_key": "immune", "evidence_tier": "Very limited", "card_verdict": "Very limited (Russian clinical cohorts, developer-led).", "card_note": "", "regulatory_status": "Not FDA-approved (no Drugs@FDA record) · Russia: registered bovine thymus extract [UNVERIFIED: not confirmed directly on Russian GRLS primary registry] · WADA 2026: not named; S0 depends on Russian registration", "pmids": "14523363;33575961;37686182", "nct_ids": "", "search_aliases": "", "last_checked": "2026-10-25", "url": "https://openpeptideproject.org/library/thymalin/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "thymogen", "title": "Thymogen (Glu-Trp, oglufanide)", "full_title": "Thymogen (Glu-Trp, oglufanide): What the evidence says", "kind": "compound", "focus_area": "Immune & antimicrobial", "focus_area_key": "immune", "evidence_tier": "Very limited", "card_verdict": "Very limited (old Russian studies).", "card_note": "Russian studies only, see page", "regulatory_status": "Not approved in the US · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · WADA: not named", "pmids": "8498021;9637345;38732260", "nct_ids": "", "search_aliases": "oglufanide ew glu-trp thymus dipeptide", "last_checked": "2026-10-26", "url": "https://openpeptideproject.org/library/thymogen/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "thymopentin", "title": "Thymopentin (TP-5, Timunox)", "full_title": "Thymopentin (TP-5, Timunox): What the evidence says", "kind": "compound", "focus_area": "Immune & antimicrobial", "focus_area_key": "immune", "evidence_tier": "Limited", "card_verdict": "Limited (mixed small RCTs in dermatitis/hepatitis B; not FDA-approved).", "card_note": "Thymopoietin fragment studied in the 1980s–90s; not a US drug", "regulatory_status": "Not FDA-approved · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · not named by WADA", "pmids": "451537;2185294;7836705;8156337;8157786;16696803", "nct_ids": "NCT00002066;NCT00002109", "search_aliases": "tp-5 timunox rkdvy arg-lys-asp-val-tyr", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/thymopentin/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "thymosin-alpha-1", "title": "Thymosin alpha-1 (thymalfasin)", "full_title": "Thymosin alpha-1 (thymalfasin): What the evidence says", "kind": "compound", "focus_area": "Immune & antimicrobial", "focus_area_key": "immune", "evidence_tier": "Very limited", "card_verdict": "Very limited (hepatitis B/C, COVID-19, vaccine response; mixed results) · Sepsis: Tested, not shown · Immune support, anti-aging, recovery in healthy people: No human data.", "card_note": "Mixed use: tested in disease (largest trial negative); never tested for the \"immune support\" it is sold for. See page.", "regulatory_status": "Authorised in Italy (AIFA) and China (NMPA) · Not FDA-approved · FDA advisers voted 17–4 against the 503A list (Dec 2024) · 503B: Category 3 · WADA 2026: not named", "pmids": "2642497;9537454;9581695;22178096;23327199;32442287;33896653;34408744;36881981;38903817;39814420;42713852", "nct_ids": "NCT02867267", "search_aliases": "zadaxin thymalfasin ta1 immune", "last_checked": "2026-10-26", "url": "https://openpeptideproject.org/library/thymosin-alpha-1/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "thymulin", "title": "Thymulin", "full_title": "Thymulin: What the evidence says", "kind": "compound", "focus_area": "Immune & antimicrobial", "focus_area_key": "immune", "evidence_tier": "No human data", "card_verdict": "No human data (immune claims rest on mouse injection studies and human endogenous blood-level studies).", "card_note": "", "regulatory_status": "Not FDA-approved (no Drugs@FDA record) · Not approved as a medicine anywhere in the world · WADA 2026: S0 (unapproved substances) applies", "pmids": "24771015;42481458", "nct_ids": "", "search_aliases": "", "last_checked": "2026-10-25", "url": "https://openpeptideproject.org/library/thymulin/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "tirzepatide", "title": "Tirzepatide", "full_title": "Tirzepatide: What the evidence says", "kind": "compound", "focus_area": "Metabolic & weight", "focus_area_key": "metabolic", "evidence_tier": "Strong", "card_verdict": "Strong (weight loss, type 2 diabetes & obstructive sleep apnea; FDA-approved as Mounjaro & Zepbound).", "card_note": "", "regulatory_status": "FDA-approved (Mounjaro, Zepbound) · FDA shortage over; copies of approved products generally can no longer be compounded · not named on WADA's 2026 list", "pmids": "34170647;35658024;38912654;39509151;41406444;42875024", "nct_ids": "", "search_aliases": "mounjaro zepbound glp-1 gip twincretin weight loss diabetes", "last_checked": "2026-10-15", "url": "https://openpeptideproject.org/library/tirzepatide/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "trevogrumab", "title": "Trevogrumab (REGN1033)", "full_title": "Trevogrumab (REGN1033): What the evidence says", "kind": "compound", "focus_area": "Muscle, bone & recovery", "focus_area_key": "muscle", "evidence_tier": "Limited", "card_verdict": "Limited (phase 2 with semaglutide; no peer-reviewed results).", "card_note": "Investigational anti-myostatin antibody", "regulatory_status": "Investigational · not FDA-approved · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · banned by WADA S4.3", "pmids": "39481534;41178728", "nct_ids": "NCT06299098", "search_aliases": "regn1033 anti-gdf8 anti-myostatin courage trial", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/trevogrumab/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "triptorelin", "title": "Triptorelin", "full_title": "Triptorelin: What the evidence says", "kind": "compound", "focus_area": "Hormones & fertility", "focus_area_key": "endocrine", "evidence_tier": "Moderate", "card_verdict": "Moderate (prostate cancer testosterone suppression) · Early puberty: Limited · Post-cycle therapy: No human data.", "card_note": "Varies by use, see page", "regulatory_status": "FDA-approved prescription drug: Trelstar (NDA 020715, 021288, 022437) and Triptodur (NDA 208956) · Not approved for PCT · WADA 2026: prohibited at all times in males (S2.2.1, named)", "pmids": "12887472;17971105;39412628", "nct_ids": "NCT05029622", "search_aliases": "trelstar decapeptyl triptodur gnrh agonist", "last_checked": "2026-10-25", "url": "https://openpeptideproject.org/library/triptorelin/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "trofinetide", "title": "Trofinetide (Daybue, NNZ-2566)", "full_title": "Trofinetide (Daybue, NNZ-2566): What the evidence says", "kind": "compound", "focus_area": "Brain, mood & sleep", "focus_area_key": "neuro", "evidence_tier": "Strong", "card_verdict": "Strong (FDA-approved for Rett syndrome; no evidence for other uses).", "card_note": "FDA-approved oral peptide analog for Rett syndrome", "regulatory_status": "FDA-approved · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · not named by WADA", "pmids": "37291210;38917793;39025065;40043705", "nct_ids": "", "search_aliases": "daybue nnz-2566 gpe gly-pro-glu igf-1 tripeptide rett syndrome", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/trofinetide/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "tudca", "title": "TUDCA (tauroursodeoxycholic acid, taurursodiol)", "full_title": "TUDCA (tauroursodeoxycholic acid, taurursodiol): What the evidence says", "kind": "compound", "focus_area": "Heart, blood & gut", "focus_area_key": "cardio", "evidence_tier": "Limited", "card_verdict": "Limited (one liver-disease RCT; failed in ALS; not FDA-approved on its own; not a peptide).", "card_note": "Bile acid sold as a supplement; failed ALS drug component; small molecule", "regulatory_status": "Not FDA-approved on its own (Relyvrio, which contained it, is discontinued) · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · not named by WADA", "pmids": "20522594;23592128;25664595;27893675;32877582;38909349", "nct_ids": "NCT03127514;NCT03800524;NCT05021536", "search_aliases": "tauroursodeoxycholic acid taurursodiol ursofluor bile acid relyvrio amx0035 liver", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/tudca/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "tuftsin", "title": "Tuftsin (Thr-Lys-Pro-Arg)", "full_title": "Tuftsin (Thr-Lys-Pro-Arg): What the evidence says", "kind": "compound", "focus_area": "Immune & antimicrobial", "focus_area_key": "immune", "evidence_tier": "No human data", "card_verdict": "No human data (natural immune tetrapeptide; no human treatment trials).", "card_note": "Endogenous IgG fragment; research peptide, not a drug", "regulatory_status": "Not FDA-approved · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · not named by WADA", "pmids": "1670648;2667894;4097539", "nct_ids": "", "search_aliases": "", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/tuftsin/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "ventfort", "title": "Ventfort (vascular peptide complex)", "full_title": "Ventfort (vascular peptide complex): What the evidence says", "kind": "compound", "focus_area": "Longevity & bioregulators", "focus_area_key": "longevity", "evidence_tier": "No human data", "card_verdict": "No human data (no indexed peer-reviewed clinical trial found).", "card_note": "Russian oral tissue-extract supplement; no indexed trials", "regulatory_status": "Not FDA-approved · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · not named by WADA", "pmids": "31228385", "nct_ids": "", "search_aliases": "a-3 vascular cytomax khavinson", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/ventfort/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "vesugen", "title": "Vesugen", "full_title": "Vesugen: What the evidence says", "kind": "compound", "focus_area": "Longevity & bioregulators", "focus_area_key": "longevity", "evidence_tier": "Very limited", "card_verdict": "Very limited (oral capsules, Russian developer-network cohorts) · Injected vials, Alzheimer's, longevity: No human data.", "card_note": "Mixed use: the only human data are small oral-capsule cohorts; one reported lower blood stem-cell markers. See page.", "regulatory_status": "Not an approved medicine in the US, EU or UK · not on FDA 503A/503B lists · Russia: sold as a dietary supplement ⚠️ [UNVERIFIED] · WADA 2026: not named; S0 likely applies (our reading)", "pmids": "22977872;25051766;25051774;26390612;28509489;28539017;28539025;28976153;28976154;34173097", "nct_ids": "", "search_aliases": "kke lys-lys-glu vascular bioregulator khavinson", "last_checked": "2026-10-26", "url": "https://openpeptideproject.org/library/vesugen/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "vialox", "title": "Vialox (pentapeptide-3, GPRPA)", "full_title": "Vialox (pentapeptide-3, GPRPA): What the evidence says", "kind": "compound", "focus_area": "Skin, hair & aging", "focus_area_key": "skin", "evidence_tier": "No human data", "card_verdict": "No human data (supplier cosmetic claims only; no peer-reviewed trial; never inject).", "card_note": "Topical skincare peptide; not a drug", "regulatory_status": "Cosmetic ingredient, not a drug · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · not named by WADA", "pmids": "18045359", "nct_ids": "", "search_aliases": "pentapeptide-3 gprpa", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/vialox/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "vilon", "title": "Vilon", "full_title": "Vilon: What the evidence says", "kind": "compound", "focus_area": "Longevity & bioregulators", "focus_area_key": "longevity", "evidence_tier": "No human data", "card_verdict": "No human data (immune & aging claims rest on developer-led lab cell and rat studies only).", "card_note": "Animal/lab data only (developer-led), see page", "regulatory_status": "Not FDA-approved (no Drugs@FDA record) · Russia: registration status [UNVERIFIED] · WADA 2026: not named; S0 (unapproved substances) likely applies", "pmids": "12587272;15085253;17152729;37686182", "nct_ids": "", "search_aliases": "ke lys-glu dipeptide bioregulator khavinson", "last_checked": "2026-10-25", "url": "https://openpeptideproject.org/library/vilon/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "vip", "title": "VIP (vasoactive intestinal peptide, aviptadil)", "full_title": "VIP (vasoactive intestinal peptide, aviptadil): What the evidence says", "kind": "compound", "focus_area": "Heart, blood & gut", "focus_area_key": "cardio", "evidence_tier": "Moderate", "card_verdict": "Moderate (erectile dysfunction, two-drug injection with phentolamine) · COVID-19 ARDS, PAH, sarcoidosis, CIRS: Very limited (mixed results) · Subcutaneous wellness shots: No human data.", "card_note": "Mixed use: the trial evidence is for a penile injection combined with another drug and for hospital IV use, not the nasal spray sold online. See page.", "regulatory_status": "US: not FDA-approved (no openFDA entry) · EU: no central authorisation; EMA orphan designations only (PAH/CTEPH, acute lung injury, sarcoidosis, ARDS) · VIP/phentolamine (Invicorp) licensed in some European countries ⚠️ [UNVERIFIED] · WADA 2026: not named; our reading below", "pmids": "10233493;10356669;12727925;17875241;18978135;20442436;22467806;27133570;36044317;37348524;39870064", "nct_ids": "NCT04311697;NCT04843761;NCT04844580", "search_aliases": "aviptadil zyesami vasoactive intestinal peptide", "last_checked": "2026-10-26", "url": "https://openpeptideproject.org/library/vip/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "vk2735", "title": "VK2735", "full_title": "VK2735: What the evidence says", "kind": "compound", "focus_area": "Metabolic & weight", "focus_area_key": "metabolic", "evidence_tier": "Limited", "card_verdict": "Limited (weight, injection) · Oral tablet: Very limited.", "card_note": "Varies by use, see page", "regulatory_status": "Not FDA-approved (no Drugs@FDA record) · EU, Japan, China: [UNVERIFIED] not checked against EMA, PMDA or NMPA · WADA: not named; S0 (unapproved substances) likely applies", "pmids": "41508550", "nct_ids": "NCT06068946;NCT06828055;NCT07104383;NCT07104500;NCT07868835;NCT07868939", "search_aliases": "", "last_checked": "2026-10-25", "url": "https://openpeptideproject.org/library/vk2735/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "vladonix", "title": "Vladonix (thymus peptide complex)", "full_title": "Vladonix (thymus peptide complex): What the evidence says", "kind": "compound", "focus_area": "Longevity & bioregulators", "focus_area_key": "longevity", "evidence_tier": "No human data", "card_verdict": "No human data (no indexed peer-reviewed clinical trial found).", "card_note": "Russian oral tissue-extract supplement; no indexed trials", "regulatory_status": "Not FDA-approved · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · not named by WADA", "pmids": "24003726", "nct_ids": "", "search_aliases": "a-6 thymus cytomax khavinson", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/vladonix/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "vosoritide", "title": "Vosoritide (Voxzogo)", "full_title": "Vosoritide (Voxzogo): What the evidence says", "kind": "compound", "focus_area": "Muscle, bone & recovery", "focus_area_key": "muscle", "evidence_tier": "Strong", "card_verdict": "Strong (FDA-approved for achondroplasia in children; accelerated approval).", "card_note": "Varies by use, see page", "regulatory_status": "FDA-approved (NDA 214938, accelerated approval) · not on the 503A/503B lists or FDA's safety-risk page · not named on WADA's 2026 list", "pmids": "32891212;34694597;37984383;38813446;39740666", "nct_ids": "NCT03197766;NCT03424018;NCT03583697;NCT04219007", "search_aliases": "voxzogo bmn-111 cnp analog achondroplasia", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/vosoritide/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "wolverine", "title": "Wolverine blend", "full_title": "Wolverine blend: What the evidence says", "kind": "compound", "focus_area": "Muscle, bone & recovery", "focus_area_key": "muscle", "evidence_tier": "No human data", "card_verdict": "No human data (BPC-157 + TB-500 blend never studied together in humans or animals).", "card_note": "", "regulatory_status": "Not FDA-approved · on FDA's \"nominated but withdrawn\" list (formerly Category 2): BPC-157, TB-500 · WADA 2026: BPC-157 S0, TB-500 S2.3, prohibited at all times", "pmids": "22856429;22962027;27847966;32334036;38382158;42757290", "nct_ids": "NCT07803250", "search_aliases": "", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/wolverine/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "yk-11", "title": "YK-11", "full_title": "YK-11: What the evidence says", "kind": "compound", "focus_area": "Muscle, bone & recovery", "focus_area_key": "muscle", "evidence_tier": "No human data", "card_verdict": "No human data (cell data only; not a peptide).", "card_note": "Lab steroid; never tested in people", "regulatory_status": "Not FDA-approved · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · named on WADA S1.2", "pmids": "23995658;29491216;36030969", "nct_ids": "", "search_aliases": "yk11 steroidal myostatin sarm", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/yk-11/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "zhenoluten", "title": "Zhenoluten (ovary peptide complex)", "full_title": "Zhenoluten (ovary peptide complex): What the evidence says", "kind": "compound", "focus_area": "Longevity & bioregulators", "focus_area_key": "longevity", "evidence_tier": "No human data", "card_verdict": "No human data (no indexed peer-reviewed clinical trial found).", "card_note": "Russian oral tissue-extract supplement; no indexed trials", "regulatory_status": "Not FDA-approved · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · not named by WADA", "pmids": "12374906", "nct_ids": "", "search_aliases": "a-15 ovary cytomax khavinson", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/zhenoluten/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "ziconotide", "title": "Ziconotide (Prialt)", "full_title": "Ziconotide (Prialt): What the evidence says", "kind": "compound", "focus_area": "Brain, mood & sleep", "focus_area_key": "neuro", "evidence_tier": "Moderate", "card_verdict": "Moderate (FDA-approved intrathecal pump for severe chronic refractory pain; boxed warning).", "card_note": "Pump-only hospital drug with a boxed warning", "regulatory_status": "FDA-approved, NDA 021060 · on FDA's 503B Category 1 list (under evaluation; component of an approved drug); not on 503A lists or the safety-risk page · not named on WADA's 2026 list", "pmids": "14709577;16716870;22151630", "nct_ids": "", "search_aliases": "prialt snx-111 omega-conotoxin mviia intrathecal pain", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/ziconotide/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "zilucoplan", "title": "Zilucoplan (Zilbrysq)", "full_title": "Zilucoplan (Zilbrysq): What the evidence says", "kind": "compound", "focus_area": "Immune & antimicrobial", "focus_area_key": "immune", "evidence_tier": "Strong", "card_verdict": "Strong (FDA-approved complement C5 inhibitor for generalized myasthenia gravis).", "card_note": "FDA-approved macrocyclic peptide complement inhibitor", "regulatory_status": "FDA-approved · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · not named by WADA", "pmids": "37059508", "nct_ids": "NCT04115293", "search_aliases": "zilbrysq ra101495 macrocyclic peptide complement c5 inhibitor generalized myasthenia gravis gmg achr", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/zilucoplan/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "glossary-of-terms", "title": "Glossary of peptide, lab-testing, clinical, and regulatory terms (A–Z)", "full_title": "Glossary of peptide, lab-testing, clinical, and regulatory terms (A–Z)", "kind": "guide", "focus_area": "Lab-Literacy Guide", "focus_area_key": "guide", "evidence_tier": "Lab-Literacy Guide", "card_verdict": "Lab-Literacy Guide", "card_note": "Plain-language reference guide to scientific, laboratory, clinical-trial, and regulatory terminology used across the Open Peptide Project library, testing standard, and observational protocol.", "regulatory_status": "Educational & Harm-Reduction Guide", "pmids": "22252914;31671336;37467878", "nct_ids": "NCT04881760", "search_aliases": "", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/glossary-of-terms/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "combining-peptides", "title": "Combining peptides", "full_title": "Combining peptides: What the evidence says", "kind": "guide", "focus_area": "Harm-Reduction Guide", "focus_area_key": "guide", "evidence_tier": "Harm-Reduction Guide", "card_verdict": "Harm-Reduction Guide", "card_note": "Evidence-based guide to multi-compound stacking risks, contamination math, and safety monitoring.", "regulatory_status": "Educational & Harm-Reduction Guide", "pmids": "", "nct_ids": "", "search_aliases": "", "last_checked": "2026-10-15", "url": "https://openpeptideproject.org/library/combining-peptides/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "bacteriostatic-water-and-sterility-risks", "title": "Bacteriostatic water and sterility risks", "full_title": "Bacteriostatic water and sterility risks", "kind": "guide", "focus_area": "Harm-Reduction Guide", "focus_area_key": "guide", "evidence_tier": "Harm-Reduction Guide", "card_verdict": "Harm-Reduction Guide", "card_note": "Bacteriostatic Water for Injection is an FDA-approved diluent with specific label limits. Contamination of multi-use injectables is a well-documented cause of bloodstream infections.", "regulatory_status": "Educational & Harm-Reduction Guide", "pmids": "40156049", "nct_ids": "", "search_aliases": "", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/bacteriostatic-water-and-sterility-risks/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "compounding-pharmacy-503a-vs-503b-vs-fda-approved-peptides", "title": "503A vs. 503B compounding pharmacies vs. FDA-approved peptide drugs", "full_title": "503A vs. 503B compounding pharmacies vs. FDA-approved peptide drugs", "kind": "guide", "focus_area": "Regulatory Guide", "focus_area_key": "guide", "evidence_tier": "Regulatory Guide", "card_verdict": "Regulatory Guide", "card_note": "Based on the FD&C Act, FDA rules and FDA web guidance. Legal status changes; check FDA's live lists for any specific substance.", "regulatory_status": "Educational & Harm-Reduction Guide", "pmids": "29183075;39509151;42752426", "nct_ids": "", "search_aliases": "", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/compounding-pharmacy-503a-vs-503b-vs-fda-approved-peptides/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "counterfeit-and-mislabeled-gray-market-peptides", "title": "Counterfeit and mislabeled gray-market peptides", "full_title": "Counterfeit and mislabeled gray-market peptides", "kind": "guide", "focus_area": "Harm-Reduction Guide", "focus_area_key": "guide", "evidence_tier": "Harm-Reduction Guide", "card_verdict": "Harm-Reduction Guide", "card_note": "Consistent observational evidence from test purchases, seizures and pharmacovigilance that unregulated products are often mislabeled, underdosed, overdosed or contaminated.", "regulatory_status": "Educational & Harm-Reduction Guide", "pmids": "29183075;29864719;30136411;31671336;38560649;39509151;41773123;42137313", "nct_ids": "", "search_aliases": "", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/counterfeit-and-mislabeled-gray-market-peptides/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "endotoxins-and-tfa-salts-in-peptides", "title": "Endotoxins and TFA salts in peptides", "full_title": "Endotoxins and TFA salts in peptides", "kind": "guide", "focus_area": "Lab-Literacy Guide", "focus_area_key": "guide", "evidence_tier": "Lab-Literacy Guide", "card_verdict": "Lab-Literacy Guide", "card_note": "Endotoxin contamination of commercial peptides is documented in lab and market studies. TFA salt effects are shown in cell culture, not humans.", "regulatory_status": "Educational & Harm-Reduction Guide", "pmids": "10567002;17910052;22252914;39509151;40398094", "nct_ids": "", "search_aliases": "", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/endotoxins-and-tfa-salts-in-peptides/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "gh-secretagogues-igf1-cancer-and-glucose-risks", "title": "Growth hormone secretagogues (GHRH and ghrelin mimetics): glucose, fluid retention and IGF-1 risks", "full_title": "Growth hormone secretagogues (GHRH and ghrelin mimetics): glucose, fluid retention and IGF-1 risks", "kind": "guide", "focus_area": "Harm-Reduction Guide", "focus_area_key": "guide", "evidence_tier": "Harm-Reduction Guide", "card_verdict": "Harm-Reduction Guide", "card_note": "Moderate for the class signals where they come from an FDA label (tesamorelin) or RCTs (MK-677). Very limited or absent for most gray-market secretagogues, which have no long-term human safety data.", "regulatory_status": "Educational & Harm-Reduction Guide", "pmids": "9285939;9820615;15110491;16352683;18057338;18981485;21067829;25331030;42395176", "nct_ids": "", "search_aliases": "", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/gh-secretagogues-igf1-cancer-and-glucose-risks/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "glp-1-lean-mass-loss-and-muscle-preservation", "title": "GLP-1 lean mass loss and muscle preservation", "full_title": "GLP-1 lean mass loss and muscle preservation", "kind": "guide", "focus_area": "Evidence Summary Guide", "focus_area_key": "guide", "evidence_tier": "Evidence Summary Guide", "card_verdict": "Evidence Summary Guide", "card_note": "Moderate: a 2026 systematic review of 35 RCTs quantifies lean-mass loss; muscle-sparing add-on drugs remain investigational.", "regulatory_status": "Educational & Harm-Reduction Guide", "pmids": "33567185;41068996;41772149;41996180;42346344", "nct_ids": "NCT05616013", "search_aliases": "", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/glp-1-lean-mass-loss-and-muscle-preservation/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "glp1-gastrointestinal-side-effects-pancreatitis-and-gallbladder-risks", "title": "Incretin and GLP-1 drug safety: GI side effects, gallbladder, pancreatitis, lean mass and anesthesia", "full_title": "Incretin and GLP-1 drug safety: GI side effects, gallbladder, pancreatitis, lean mass and anesthesia", "kind": "guide", "focus_area": "Harm-Reduction Guide", "focus_area_key": "guide", "evidence_tier": "Harm-Reduction Guide", "card_verdict": "Harm-Reduction Guide", "card_note": "Strong for GI effects and gallbladder risk (large RCTs, meta-analysis, FDA labels). Label-based for pancreatitis, thyroid C-cell warnings and aspiration.", "regulatory_status": "Educational & Harm-Reduction Guide", "pmids": "33567185;35344001;35658024;39471342;39482213;39509151;41996180", "nct_ids": "", "search_aliases": "", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/glp1-gastrointestinal-side-effects-pancreatitis-and-gallbladder-risks/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "how-blind-retail-batch-testing-works", "title": "How blind retail batch testing works: the Open Peptide Standard chain of custody", "full_title": "How blind retail batch testing works: the Open Peptide Standard chain of custody", "kind": "guide", "focus_area": "Lab-Literacy Guide", "focus_area_key": "guide", "evidence_tier": "Lab-Literacy Guide", "card_verdict": "Lab-Literacy Guide", "card_note": "Policy: describes the published Open Peptide Standard (Protocol v1.1). Why it is designed this way draws on published test-purchase studies.", "regulatory_status": "Educational & Harm-Reduction Guide", "pmids": "29183075;38560649;39509151", "nct_ids": "", "search_aliases": "", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/how-blind-retail-batch-testing-works/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "how-to-evaluate-human-vs-rodent-peptide-studies", "title": "Why rodent peptide studies often fail in humans (and how to read preclinical claims)", "full_title": "Why rodent peptide studies often fail in humans (and how to read preclinical claims)", "kind": "guide", "focus_area": "Evidence Summary Guide", "focus_area_key": "guide", "evidence_tier": "Evidence Summary Guide", "card_verdict": "Evidence Summary Guide", "card_note": "Based on systematic reviews of animal-to-human translation, FDA first-in-human guidance and this library's published grading rules.", "regulatory_status": "Educational & Harm-Reduction Guide", "pmids": "17175568;20361020;20361022;23401516", "nct_ids": "", "search_aliases": "", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/how-to-evaluate-human-vs-rodent-peptide-studies/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "how-to-read-a-peptide-coa", "title": "How to read a peptide certificate of analysis (COA)", "full_title": "How to read a peptide certificate of analysis (COA)", "kind": "guide", "focus_area": "Lab-Literacy Guide", "focus_area_key": "guide", "evidence_tier": "Lab-Literacy Guide", "card_verdict": "Lab-Literacy Guide", "card_note": "A COA is a seller-supplied document, not proof. Published testing shows labels and purity claims on unregulated peptide products are often wrong.", "regulatory_status": "Educational & Harm-Reduction Guide", "pmids": "22252914;29183075;31671336;37467878;39509151;41445733", "nct_ids": "", "search_aliases": "", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/how-to-read-a-peptide-coa/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "hplc-vs-lc-ms-peptide-testing-explained", "title": "HPLC purity vs. LC-MS identity: why one test cannot replace the other", "full_title": "HPLC purity vs. LC-MS identity: why one test cannot replace the other", "kind": "guide", "focus_area": "Lab-Literacy Guide", "focus_area_key": "guide", "evidence_tier": "Lab-Literacy Guide", "card_verdict": "Lab-Literacy Guide", "card_note": "Based on analytical-chemistry literature, FDA impurity guidance and the published Open Peptide Standard. This is a method explainer, not a product rating.", "regulatory_status": "Educational & Harm-Reduction Guide", "pmids": "22252914;25044089;26719571;29864719;30136411;31671336;36949371", "nct_ids": "", "search_aliases": "", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/hplc-vs-lc-ms-peptide-testing-explained/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "immunogenicity-and-anti-drug-antibodies-in-peptides", "title": "Immunogenicity and anti-drug antibodies in peptides", "full_title": "Immunogenicity and anti-drug antibodies in peptides", "kind": "guide", "focus_area": "Pharmacology Guide", "focus_area_key": "guide", "evidence_tier": "Pharmacology Guide", "card_verdict": "Pharmacology Guide", "card_note": "Mechanism and risk-assessment methods are established in regulatory science; clinical rates for unapproved products are unknown.", "regulatory_status": "Educational & Harm-Reduction Guide", "pmids": "37467878;39185315;40398094;41445733", "nct_ids": "", "search_aliases": "", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/immunogenicity-and-anti-drug-antibodies-in-peptides/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "n-of-1-self-tracking-and-observational-registry-methods", "title": "N-of-1 self-tracking and observational registries: what they can and cannot show", "full_title": "N-of-1 self-tracking and observational registries: what they can and cannot show", "kind": "guide", "focus_area": "Evidence Summary Guide", "focus_area_key": "guide", "evidence_tier": "Evidence Summary Guide", "card_verdict": "Evidence Summary Guide", "card_note": "Based on methods research on blinding, placebo and N-of-1 trials, and on the published Open Peptide registry protocol. A methods explainer, not a product rating.", "regulatory_status": "Educational & Harm-Reduction Guide", "pmids": "15333621;18316340;20091554;20685078;22371859;25976398", "nct_ids": "", "search_aliases": "", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/n-of-1-self-tracking-and-observational-registry-methods/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "oral-vs-injectable-vs-nasal-peptide-bioavailability", "title": "Oral vs injectable vs nasal peptide bioavailability", "full_title": "Oral vs injectable vs nasal peptide bioavailability", "kind": "guide", "focus_area": "Pharmacology Guide", "focus_area_key": "guide", "evidence_tier": "Pharmacology Guide", "card_verdict": "Pharmacology Guide", "card_note": "Oral peptide absorption is very low without special formulation; the best-studied example, oral semaglutide, reaches only about 0.4% to 1% absolute bioavailability.", "regulatory_status": "Educational & Harm-Reduction Guide", "pmids": "30781867;42687069;42797346", "nct_ids": "", "search_aliases": "", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/oral-vs-injectable-vs-nasal-peptide-bioavailability/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "peptide-degradation-storage-and-cold-chain", "title": "Peptide degradation, storage and cold chain", "full_title": "Peptide degradation, storage and cold chain", "kind": "guide", "focus_area": "Lab-Literacy Guide", "focus_area_key": "guide", "evidence_tier": "Lab-Literacy Guide", "card_verdict": "Lab-Literacy Guide", "card_note": "General degradation chemistry is well established; storage limits for any specific unapproved product are generally unknown.", "regulatory_status": "Educational & Harm-Reduction Guide", "pmids": "37467878", "nct_ids": "", "search_aliases": "", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/peptide-degradation-storage-and-cold-chain/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "peptide-drug-interactions-and-contraindications", "title": "Known peptide drug interactions and high-risk contraindications", "full_title": "Known peptide drug interactions and high-risk contraindications", "kind": "guide", "focus_area": "Harm-Reduction Guide", "focus_area_key": "guide", "evidence_tier": "Harm-Reduction Guide", "card_verdict": "Harm-Reduction Guide", "card_note": "Regulatory: every interaction here comes from a current FDA-approved label. Interactions for unapproved peptides are largely unstudied.", "regulatory_status": "Educational & Harm-Reduction Guide", "pmids": "18981485", "nct_ids": "", "search_aliases": "", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/peptide-drug-interactions-and-contraindications/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "peptide-injection-site-reactions-and-infection-red-flags", "title": "Subcutaneous injection-site reactions vs. infection red flags", "full_title": "Subcutaneous injection-site reactions vs. infection red flags", "kind": "guide", "focus_area": "Harm-Reduction Guide", "focus_area_key": "guide", "evidence_tier": "Harm-Reduction Guide", "card_verdict": "Harm-Reduction Guide", "card_note": "Based on FDA labels, infectious-disease and allergy guidelines, and outbreak reports. It describes warning signs; it does not tell anyone how to inject or treat themselves.", "regulatory_status": "Educational & Harm-Reduction Guide", "pmids": "10511524;17910052;23886784;24973422;33204386;39509151;40156049;42692277", "nct_ids": "", "search_aliases": "", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/peptide-injection-site-reactions-and-infection-red-flags/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "research-use-only-peptides-and-fda-503a-503b-law", "title": "Research-use-only peptides and FDA 503A/503B law", "full_title": "Research-use-only peptides and FDA 503A/503B law", "kind": "guide", "focus_area": "Regulatory Guide", "focus_area_key": "guide", "evidence_tier": "Regulatory Guide", "card_verdict": "Regulatory Guide", "card_note": "Based on FDA primary documents. Legal status depends on the specific substance and changes over time; check the live FDA lists.", "regulatory_status": "Educational & Harm-Reduction Guide", "pmids": "42752426", "nct_ids": "", "search_aliases": "", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/research-use-only-peptides-and-fda-503a-503b-law/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "wada-prohibited-list-and-peptides-in-tested-sports", "title": "WADA Prohibited List and peptides in tested sports", "full_title": "WADA Prohibited List and peptides in tested sports", "kind": "guide", "focus_area": "Regulatory Guide", "focus_area_key": "guide", "evidence_tier": "Regulatory Guide", "card_verdict": "Regulatory Guide", "card_note": "Based on the WADA 2026 Prohibited List. Athletes should confirm any substance with their anti-doping organization.", "regulatory_status": "Educational & Harm-Reduction Guide", "pmids": "21752560;29183075;30136411", "nct_ids": "", "search_aliases": "", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/wada-prohibited-list-and-peptides-in-tested-sports/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" }, { "slug": "whats-really-in-the-vial-net-peptide-content-vs-label-weight", "title": "What's Really in the Vial: Net Peptide Content vs. Label Weight", "full_title": "What's Really in the Vial: Net Peptide Content vs. Label Weight", "kind": "guide", "focus_area": "Lab-Literacy Guide", "focus_area_key": "guide", "evidence_tier": "Lab-Literacy Guide", "card_verdict": "Lab-Literacy Guide", "card_note": "Based on analytical-chemistry literature and the published Open Peptide Standard. This is a concept explainer. It contains no reconstitution or dose calculations.", "regulatory_status": "Educational & Harm-Reduction Guide", "pmids": "16687256;26719571;31671336;36949371;40872554", "nct_ids": "", "search_aliases": "", "last_checked": "2026-10-27", "url": "https://openpeptideproject.org/library/whats-really-in-the-vial-net-peptide-content-vs-label-weight/", "license": "CC BY 4.0 — Open Peptide Project (https://openpeptideproject.org)" } ] }